var title_f1_29_1488="PET";
var content_f1_29_1488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 647px\">",
"   <div class=\"ttl\">",
"    Peritoneal Equilibration Test (PET)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 627px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Based on standard four hour dwell with 2.5 percent dextrose. Can be used to classify peritoneal transport.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data originally published in Peritoneal Dialysis International. Reproduced with permission from: Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138. Copyright &copy; 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1488=[""].join("\n");
var outline_f1_29_1488=null;
var title_f1_29_1489="ICE normal MV";
var content_f1_29_1489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Intracardiac ultrasound examination of a normal mitral valve is shown in diastole and systole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that individual chordae tendinae are visible and the thin leaflets of the mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1489=[""].join("\n");
var outline_f1_29_1489=null;
var title_f1_29_1490="Cutis marmorata";
var content_f1_29_1490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutis marmorata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEWAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6hjkDKdySKRz8w5471nQ+VCwuEeWZeUY7uBk9hWscMQu7kc8GorgxRQkvtSNuDx61SZJlX2pRRwFLeUiQ/d2rwn19TWPcy3V/5CwKYmAYtKxwT7mtGS4iF1sUReWmHiXJ3Men51HMl3d3SiS3EZRPuo33s+taLQDl0tHIZTcFkRiS2c5P9aZqGn3kSRSm6ba3KIR2+vausuIhbxrOIYFKfK0bJnn2rC1S6RLpPtE27PO0HaB789q0TuFzGuIdQiiSMSuIlO8ZH3j6+1Z8Ec9xKZJ43cEEKqnGB6mopfE0ktzLbtOZIyDhVA4/GtjRZTLaqL1CZ0AIULgEH1NaWaWoXKqSzRymW3uZoY4vlD4wuOmOKuWuo6rY7pXiwkpwmRn/AIFW/b20U1s6TQ7CnzqMZXPpVS9m/s4xtdfu4/vL8wbA7jHapunoK9wGsSmNY2aE5IJWFNpz3Jx1q7Yxymbfb3DbF+d2Y9vYd6xJPFFhHMRBaKmCAHVsZHvis668TWIEhiaSLzRjbFkhfoD3qdC1Tk9kd1aXcdpA08hBSSQjIGST/THtVS81KWeSJ5YN6oxBXJBx6+3FcEPFscciLb273CL180hc/QCkl8R38sUqQ20cNvKeVMhbn1qPdRosPUfQ6DxRqMNjbCKAMwn++rc4H1zzXnHgHUns5tU055sKk/mIM9Aa2buW51CDy7iVfLzjCrj9azBoNp9rkvAh+1Pw0m45x/KtI1oRVmDws2dM2o28S75JRgHnJrJvPFVlBGzNMTjICqRWLqqQW2wNa3d0TxiFN/4n0FJJpsBRN0G8DoSAMfpT9vDsUsHLuY2u+PUQSiKcZK8DNcpZX82r3CTXErCMHIBY813gsEJyIIG45xGvJ/Kr8Nuo4ZEUY/uVf1yEdolPAy/mKekajFbqBu2gDqD19q6ey19NwO9hjoeoqotnERlY42PtxVW60/KlghUdeDms3ioy6ELBu/xHVw+IYz8yyYA/GrB8Qqvzo+cD1rzOazfB2synOeDzVYxSrISs0uCOpY0vbQZp9Ql3PXYPEqsCFcEYzknBpV8Rqzncy8Dsa8mja4KgtPKdo7P1qZDO/wAxckdMA80e0gJ4Ca6o9VbxDG3MhHTA56VXk8RDcRvUexPevNwJyWBkcFugx/WoWSXJIZg3qec0e1pk/Uqnkeh33iRIk/1oGDnA71zt94ujQEtOVI5Brkbmz8wt5ksp+j4NZd14YsrxG33N+o9FmA5/KrjUpdQeDqpaI6G68e28RKws8kn91TWlol9quuXCo9x9jgbsOuK4608O2Ni4NsJhx952DHP5Vs2Us9k7fZ3yxHO7vWrrUUvdMngsQ3qvxPTvC+n2+m3hlaZp2Lf6xjniuvvvENtBGxV856Zrxy31+/EQULAqj2NVbzUL++A3SBeOQnFc05wk7tlxwdRdD2LTddt7u4K5Y5PrVm91a2hy6t+86En0rxqw1G+tI9lsqkn+Jsj9ahv9S1K7XJlMW3g4XIz6dalyh3GsJUe6PR9U8TRRDeZynBOAeK5KbXnvGGyR8k8DPFcXd2+oTsC98oHoYzz+tPtxeWYzviJ6jgg1alDuX9XnHoeiaVZecQ9zITnuSeK66wsoUwEkQ4968ktvEF9CRuMbAehxxWjD4zuEba0QAPAKmh2ezIdKp2Pa7dIIiAjdR+lXo5V8wuuGUcdeRXikXjlR97cpHFXYvHkKrtVih9qjkuZunJdD2FvvArIGUnOM4xSJIQ2eVUep/wA8V5VbePYN3EuG757VZPjyLG0uN3OOcYFL2bJ5WejyXYA56Zzk9jVaS+jGIxJxnJHauEHjS1MbMZEBI5yRWZe+N7KKInzFVj7imqbFys9AvNQSMqAVBU+tc9qevGFivmrtzzlsECvM9W+IcDBhbytJJ0UKO9Z2nxXesyM15M6K3JGev/1q3jStqyXZHTa14tnun+z6cpkPT5O9NsNFv9RkWS+mZY8fdVulbOiaZYWcY8pVbHA+tdBDtXCqF68YH8zTulohHgvxM019E8WvGrSC2njW4Q7jzkYOP+BAiuOuPMILBn49G45/Gvevi54fk8ReHvtlhE0mpaaWdIxyZYjjeo9SMbh9CO9eDwzLJAGADAds4/ziuGonGR6mHkqlO3VFE3DxjazOCDySTxUkc8jSxgu2MgZDe9PuIo3UcqTjJA4rOKPBcISGZcjgChO4SjY+/FuhCryTCMzRjBEefn/Cs6C+hkgeS/ubeMSE539U/A15HdX+p3GWn1C6f+DCSEcfQVlyQcEsWcE8eYSTj8armiYxwknuz1W+8S6dBI1mt7A0IOY3XDDOOpI/lWVP4yeR/MWV/NQ7UaNdoI/+v6GvOPs8qJG0JwrduDx0qdEnkHzOAx4x1/Gq510NVgl3Otv/ABVcTTLJG0nmZ+YORg/hXE61aS6tdyT3OpTr5nG1AOmenPSr1tZkpukUHg5LHn8MU5F2OVjhVogMAtj+ZpKu47GiwsEZun2senuWtRIzKSMk54rUj1i+IJR5VBG35T/SrUcexVLIpHUFf60zHz527e3y9frSlWk92UqMF9kjNxflcvLMyk4wZDimETzbTjYCeWxWhHbl0D+nUMT1oK7jyFA/u54rNzKSS2RnR2kxb558ZPHGRTZLWJWJkO4g4GOKszRTFmMe1cDpu/lT4YQR/pDjPX15pcxpbqUJIsE+Wu1uoxSxhUGWzuPJBHFa8scA5JJJwAKy7mCaVwwLeSPfBocio6mhCU2BiAB6Zq19pUbQkSfgay7W3dtvBkXvlu3pV1JFQDYCBjgZyKlsiVNMm8xpOUjQEcHuKhuFJiDSLnnBxU0BTcrOR9RxViSWFkbYVZgM+1LmJ5bPRGXDbRmXdHkD1NW5FiVRuAXOMk0huYvLxjYehzST/PEFDLgqcFTSuNxbepKI4VXkgN61UvWkSQmPDr6j/Co42JiZV+Y+h71lXAuBu27toPI9DRe5UKWurG3DZjbp15NVpFTzAFbbwBnNQl/n+c85+6elSyq7TKNgIPTbyBV3OlRsPgKxFhMEdTwp64q1HaxKrSQFVccsBzkVHDGoY+bGcdMA9ak8jypTJDjA5xU3JcUPt9/J8tiPfk1LJLGq4dQODwy9PpVmEl144Y87gKdcWectIDkjkmi5lpfUybp0RDtMOG52sMEVSkyAphiBB4PpV25gVvvFnK85ZcZ/EVLZxxl2R1bd229KVzdJRVzNj/dsxZAAR93GP1pHVM5VgR/Kukl0yLyAQCODjuaxruxfzCUwcdV7incUZxk9B0FruQFMuuOg4qU28kil9xDAYA6cVDbrJAMnKKeu3nFSeYzP98geh4IHrRchxdxrKsagK5cnOVFQsI9uYwY3PQA5zUihmlKsoI9c81Mtm7soKZUcD1FIqyW5SWTJ2/M2fcfjTJ7YsflOE988Vo/Z41faVGD6HFD7jjywN4Oc460cwr9jH+y4Pz4YY4OKjeOEKoGNhGcGtZoF25YESd8GqNyiqpPl/uyfvCnzAveKbQxE5jA9dwYGm+Qi5IVie+T1q2kcT/ISOM89KWa0/d53BlHQA801Jg4rZlT7IjqWiIAHYGqs9q8B+QvkfhVllZMLDu2nqoqSFLh8fOpwM7c9KtTZnKlbUyHkZQyurgHqMZzWfd6faXSqsiyepZZCp/w/SukeyeSMngHvuFZ81pMpbC7SORn0q1Wkupi6FOZzyaRFaPvt5pUOerjcP6VrW2r3NrgxyI20c5HakaBnHzopGe5xVSa0dSSqHb/CCeRW8cVLqc88HDob9v41ngQb1YDP3l5/PFbOn/EJHZQJgDnBORXnc6uuMKTjnkd6y7vYFPmxAr3bOcVrGvF7o5J4WS2Z7/pvi+KUqRICR0wK4n4geC1v5bjXfCqJ9ob57qwTjzD3eL/a7le/bng+XJqc9lzb3LheoBOa39K8e3NrgXD4Ax9w5496uVOnVVkzGMp0ZXMOOdLr5Wb5gcHPBU+hHapPlEiptbG7o3Irp9Wm0DxgTcPN9h1XAH2uIfex/wA9E43fXr79q47ULbUNFuETU4wYWcLHdxfNDJ9G7H2ODXFUw86e+x308VCqrdT6DeExszJjOcjB6UrI0mWkCqo7luaSW8mBKbOV5JPWmT3ylVjMLsScliMY9q5OY9KNJkIZYnYgkK2STjt7U6CaJgoyoLdCvHFQGQyXO5SiljkLgjjPSrawoky7GymSNrdRQ5Gjp23LC3EaRnbHgdc1Xu3HlEmHcCPu84NXIUQ5JVR23ZxzTJ1QsVG8E8tkdaXMQoq+xShnnktgkS7A3I7rVlDJGEEgGSOpNT5SYxIn7sj+6OaW5s3kTLFiT0I4P0quYLIZHO0iYdijAjjPBqW4aLyeGAYD5hj9RTDGdjKFwmOTjNNktXCoPLycHOe/vSFyK5FHE7n926sOeRxx706CHJJyWT69PwpIJS3yyRfvACOeMitO08sIY2RVGMknjNO9gkmigIMMXVyc+pp8sMjxqFzz0OattGsY+Tdg8kD61oQRsFDNjBHINK5LdtTnmtDlRIxIPoeKQLuYIu7K88ZxW5NbFtxPBAHAxVG7t5BA2GGenHUfSncalcy3a43oig8AHJ53VK0EzqcYHqBS2lrIso85pdp/hzgCr0sEixuImYemc5xQy7pOxnNANpXzBg8kDtVMtsmQPKPLVuV9a057VBFhpGYnnGKzJrAInMh9/l4NCKVurJJLiBFBV9jgcjGSKqXQMiq7Sqxx17UtxpzkDZJtH8II61Glo4RlU5I5K0yko7pleEOMkojFuDVq0hVMDq5HDZzg1FHDJvBwxjB5OOtTRW04UNHlsnqBjigcjQgErFUZVOTgcCpPmjkJmGNvAC45FVImk2uGbDA/dNXYL2JwVkf5wMZI+99Km5DiMa4/ergqqdADwamd3eN8sSAfr+NRo/mSttZcHB2sP5elTIsQchuGPPTg0GckkMMSvGFlGCeelOhtIQxILZGcY6VPJcKqlWVSW6YPQ1TMxz8oxn0GQaNCVzM0CzLEqlsYH6+lVTtAbzFCtgmovtjOucBsnO7OSKrXSySyOWydwyOKLijT7khhhZm8kqWb05qhexMHZw65OAR6VMtjK8oC/Kv8O3P4mrEWnlWZpRvO37xNBqrR6mdwsY+Y7cjkAVoxOGiJ+bcRxk5qobcB12MwjzyvUVYtpI4VCENluvcCkOWuxHLF5jZZcNnp6/hSrEwYMH2gDsKt8SyHDYCtg9sVIItyksWYqevSkRfuUmijJDlxg98evtVS4YBGwQe3PetKSFcKFYhucADJI71DPErufLQrjuOMU7jVjAus7SUGCR1UYxT4MeXt84mQDHPf6VeZn8pgxREHAyAM/Ss68LRkZdNzcZznj6U7myjzaDpYSWZkZcHG4Z71AcRzhiMcEZxkUxC8y7YySB1YN/ninwwPv/fsRETgFuRTY+W25MZMZKueRzzyKhZm3/K289SD6fWpliDM8USE+pznj29qqywNEcqNrA8DHzfSi5h7ONyOeNGBOOvIPWqksbmM4wfYdK0I33Id6bGXvTzGWj/1fGefrVXZnKNjnngLptlG1hyT61k3tmF+YAMAuOlddPA7RADk5ycdvrVR7dTGd2F9cDJP1pqRm0jzu/sUzuV9zdTjjArFurOQISjblPOSf0rutRtFO4uAB2BPJ9qw7rTeroGAI6EcfhWsajMqlFHFvPJE3yOVOc9ga2dJ8WXtuRBcYnt5CA8cgDKwz0INN1HTZDHkDk9xWG1o0cyEZ27gOnWumNeS2PNqYdJn15KrSuQ8gJcngjkfjRHBvOyLJZuWLdqePLMrjbuODyTUkdxE+2RdxA6kfKc15Gx9LqthklsgZEAUuO6rzn1qAISWKx8L2Bzk+taESGSGUkAO3cN/9aqsED+YS8hdTgEY68d8U7jWzETEm5HUmUgZdugNRq2WBI3dj83GP8KszWeHBcrv6E57VVjRP3iszMpbB496LiST2LkBXzQhdiynPHUVqXEYkGACUxypPWsS3DWsqjazgDKt0/DNXYJXkG4EbM5BJz+FBMoa3LVnCqx42ghCSAeSKsRIuwiNk4bGBzmnpEdpwV3Z4qJo1nJjRypXrgYp3MnqyFLZfOLMhIHqKiyQ+w42ZwCemKuoAGUFjkcHJyMVMsK+UcKDjgAdfrTuLYrYTZlV3YwMjg1KECKJHB45JzmnxF1G0x7d3JB/nVa6cscxspHTaKV7jjHoWLhl8oOuSOpUDFZ0VwBNlkxuPIIyRV2xgLWwZ8sw5wTjn6UW0CpM7PIGfHCdMf40AkldFG9nKMRGGdsZAxx+ZqG2nubnAm8sL2x941sm2jjHmsAXUEgEcr6ioiiKiMiKevQcnPWi4/dtsVI7VZU+XBJOTzxSXdkxIIyc87W5wRV222/KJFEZzgDtVuVQdxJGM9Tmi5m3ZnNyxlE5jC44IzzUdrC0pACAe3oK1bqNJHwWzjk45qE7gNqPiQd+xX607lKWhBc2y/JwMjkjHWpGhiCPJwrAcbB+taVuoeFnfcDjBbFV7u0VFVkCMxPJb+lVcnmu7HPTxFWJjGRjJAHX8aqeRIkZ8sY3HOcVv+V96RQFZTyTyQPpUF4ocMjiQq3IOeD9KVzoU+hm2yuJFExwwHTsfpWjFHvjIzhegPeqJiijXYWJbp82RitCxWRYgrtjPO4DOf1pXFU7iLaFnA4bttPNJLZ7lRGwP9kHrz7Vrxx7FB2AE/eOM4pVgiJfBYOTyQMfrQc/OzDNmvzgLh+MnHQVOsQaIhCEYjqRWlHConG5TgdDjNPnjjjckKGU8jgcH1oDn6FCOF0IK4PTDHiid1ChcngY+taMaI0LAA7ycHiqstkQxYMNv60Amm9TKNssrlgh8thzwaSS1i2Z3YjPAHpWirmAOsuWGBkgdfrUDzW6yHCbz9772AKVzTUooXhmYgbohwpc5zUyToEycce3B+lK8O9jvPy9lzVSe1KnEefU5bG05phZPctSsnJc9s8Lk1k3bMhZoWbaRkgDgVPc70lRCkbAoG+U7gOM4z0zUaQTTb5HjA9AOce1NFRSjqzOmjd1Hztjrk9f/rVBLZeUQz5J43fNnH+HWukVRGUVk4xgnG78azL9FMx2oHJ4IXp071SZpGbbsZsYKNjahzxtUEED1qxAN7IrFET2JJ9KnghaUbk2omQCwG78PSrSWjAMwQdMjuSPX1obCUkVrcRWshXywH5Ge1OG1nYEBR13Y6/WnzwFkBAJHQsD92pYwIogAhL/AMGDgZ96VzGVtynLYtIBlQQAT6cVUkt9u4hsbexrWErqMgAjoRngj0//AFVTvFdsYQj+p+lMlXbszPkgaZdyI+7uBVZkxkFWAB4z/nmtc7VcfM24ryDVW4haVvkQlyeMZ4pk36M5q8sxJIefmzuIx1rMltCoGDkD1NdZcQzRN86dv/11lXMajIVVYBcHj/Oaa0KvdHKXltKpDKqsOmfUVgXVqVnBKANuGQR057V2EySMfl6KMFccVUMId1EiqckA5GStXFmFSFj2zcspHzHPJO3gsPpRmTeDE/7sHOSnWq2Iy+EXndlsjAP0NXEljiXYiH5hyT0Hbua4z1LW2LVvJKxMYKPk8bTxmr0axhEDAk7suB1HWqJl8oCSJVcF97Ns5PTOauWzCRR9wK7buDwD6/Q0GUl1JJYI5JAMDJ+bg/gM/lVKK3b7QUDbDuwWJ4yK1V2MwaQbcdm6n6VT6SOARsc49vX86ZMW9iGRklkSJk5HGQOvoeKdF5ls5KrvAJBB5B9DUzWuxNyFgAPkfGefQ0rPFKyx7CCo5IHTsaY79FsTQ7lRUZhlhgkjv2FWbaHyTuYkyHgBu4/pVYGOInG9goPPofpT7d5pSzFsMF4BGDjvQQ1ctRxqyklAAM529KdAROwH9zkAcE05Nu1Vxt65U8Z9qZC5hlbGQ4HAHWgncWa3XDIVJDHpnkd/yrK2+TKBGCU3YyeBnPStnzAxxlQ3bn+lVJcicYUts5yo4JoKh5iTXJj2/KgHO456H8KLcmUBwOgGDjNTCEOpTGcYYnFRSrIEKj1wpXtQGmyIbyeZpVVSCM+mM+wpn2prdkaOIsvcEc4pI42cu7hdoPfqeOtRi3YwiSYgoDg4btTLtHZlsXESjzJlbBGAOvQ9sVPdXSHaBuUnkjrmufnQ+XmPd8p5YDjB7CqpbE4eVmIJAOcj9f6UWY/YRetzbm2syyFgrZ4JOMio/tBRirrhCeeenv8ArVU3awp5QHGc7sZHfvWebl2dflJ2jIG7sOv9KpIj2R0QmjWMIpOCOo5xTLhv3ZCMxY5GM5H4e9YUdx9ocnYY1ByGIOPerMzD55MHzRgdSBn1osT7KzKd48lursDKFPUJ0x0/OoYnka4RCn7sD5N2R168VMJZGmCuAxDE85PfqMda17eBGxshjOByHJHOR07dBQjZyUVqUWtsY8zcyjByxzj2q7ZSBcK0hTax25Az/hVtliKlOq55U9vYmoBEiRHO3nJUMufxz2pGDlzbjJbp4gVU7v4d59fbH1qezmM0RZwYwowVJBz6fWqpRWl2yxnbkndvwKuPhIBxGMdOOc/U/wA6CZJDJDKmx1BbjPHUfhTXLSYaZTuPPzED+VWFkMhCY+WMdOg9uRVS8aVVJhKBm+9jqPxNBKRMpAVs5wBlec59uKW4/eQbgcNjnHNYS3iNMY2Vvl4UjJGc9P51pxyLj94COPmzwMn2osXyOLGZEXOWywyAfx5qhPbgIGRzjABPUVde5QmTaVwBw2OD7e9PUCWJcqsZ65Ydfr60WNLtamY0hB4U9OSTjP4CkmWSRfl389R0HHpWgtooXMeVPfB6++alt4REx3qoyNrMOu3vj0pkOa3RgpaO6kPg7W4DcjHritaOA7VGdgxwVAOfoKlZAr7lTnOQo5PNPKRO4bBRcfxgcCgmUmytKjspVd2SMjjtnqfT6VRgs/Nk3uwAY4wDjrxx6VroY12tGDgjkHp6dKlkhdiy4yqkblwA2M9KLk8zRz7ad5a7xtX+FUJ6+tW+RAFPyv0JXjr2Aq3co8TABPlYYBft6kVEZIxHGsucn7pA5H50xtuW5QkXyUIOXUHlj/Cf8arLG4cl1+QngchuvJrTeRHLgJjt90En3qNbBXVwMsuQxB5oQ723M6SMGZWzJsA3F5BjA9aiF3uUrHOcDr1IB7cVZmt3WSQYKsvRc4P05qjJaGMvJCoTjnPY9/zqhqz3GqdrrMGAAA3ZFWInhP3t2eSMHp70zy1ifG07WXHLjnuOlStauP3kSkKcA5XH0wf609iZJPca8aSxkMFJK9+9c1e2KrKQoZGPUY461ty3DQybXVgzHhW5PseKhuhJMMSBgedvbHFVuTFOD8jjL1LhGDp0U1nLLIZV8xSoD8D8a6ee3wcKuFGeq8lqjk0iNmidUTseeaaNZOKWp3N3Fk53c7j8wbGKpx301rOkd4wKkYSQdOfWrFwjBiWO3Y3Ixj6VDfWvmxDcu7cMbTycf57VytXO3Y3ImLyxtGdzcfKOhOe1XUvEZNu1QUYj2J9a85s9Uk0K6SGZy9nJ8iSE/wCrbptP9DXZaXcLOC25gSOFB/l+tTsZzhbVmukgctklHzwQe1SOnlAGPDjndznJ9qpu8vm9MY7Fvx5NSPOJGBUruY4IVcAn396Zna5oWMpmZosbM8nI60gg8u7MzgiPOCKsaVDndiRmJyWBI4OOe9T3i/uiF3Y6cjH40zNztKyMa8Us+yMHLYbIGVx2FX4nCPGSPnjGdvU574qO3Zo7k+aVcdBxge9TSRoSrruDE5Qe3f8ACkaN9B+pEEF94UqR8ufvZqKAsWGUPyggc+3erGFUqkkayvyAG/oPxqtlYrlN3IXJOBgNntx7YqvMmL0sXll4jYqAxwQSOv8An+lTpEH3MQMHgYGKrllePCgegAqe3kaJQoUgr1weKRm/IQKUG3J6E8VLFAPLyoBYkcAdzT4pFly2QMc/OcU9yYIflZhJkc4zx6YpkNvYrXdsFBZUBGM9eM+9UriJHjOAqx9cCr0k5l4wFXJ/zxWNetgnAV4xjJHQCi5cE2RiFdjO/wDqhxnafyFZj4luHzsVAwIGOmeorQUOZzt8wANuyrDCHPp/KrMdiscR8/crZycDrTN1Ll3Ml7FZlfO1i2WVvXFFtb5iAkA87glduW469BxW3FZuWfYA5k+YN0wfWmCwBlGVCgjJyenvTuQ6ifUrS2MO1mReG5PuMdh2NUbi3CKArlgccMMYPofXvXQW0SrOoEjFQd3TJHtnuKhvlhnLFlj28cAdMf04pXIU7Oxz0f7mZY9oZB8wX6nkA9K0Ig8qAI+1VyCp6j6+lMnj8obVMYRlKYxzj+tLY24jiSQ7uoC7Sc5xyabKk7q4kYkUg5G9eCT0P/66kE4dSrlZGxn7p6+lWbiJ3+QZ8t1BJzk5/wA+vrTJo41yYkffndkjgH8O1LczTRBDIXfoCwOQGH8x3qcQh4yXRf3nGRn0qKOORpXdNrIfl+f1446cVewASNgzjAO7nJ6cUhy02IYMFWYIqeWcKC3UfSo5sS7llYtCvIATrUTylWdNoCuM7h3/AAqSLzZW+cFhjhiMDOf/ANVCQrW1Mu6tscJuVv4SQAKY/mrG7YUHPIwcDA6k1u/Zx828Ajr064qrLYidsoylifukZx3z6YFUWqi6mWqMQoDEEj5ivOcfXoKuC237C+FK9WzzWlBpQRdwQNtHBKjBFSzWaRDEZAPcAc0ESqrZFVkcKexI6dfxzVW4kcSYeVlA/wBo4J9DitFY4dwd1bpgknr/AIUt1YGVPMCMpUZUH5htPqaRKavqYNuJHmBeRVj5JzxUkchZsEZC87QMZ/H1zinx286sPJXaoydzDOR7Zp62rCUu4yoGApbG0nGSPWmW2iwkCyffcneQeTxn0x61oiLcqrh8kHIBxyO9VI/LUo4dmBTcMHnjpU6TSRja7bsnJGMYz3zj+dIwldknlJtUy/Md+c9cfSse7t03BVSNsNkEYAGfetIXMinzAhKR8D5cj/8AXWXKVcq6SOr5LFmHI/pVIcE0xwhQW5YbcA5O0lmyP/r1DNGysHOS5HyKTkj/AAFSGQEfM5cbssCMEf59KYNjtlC8eQR06fX16U7FakT7GLSvDl8Ath8lj68/yqp5Czl2kVxGCMLzjOe9aJZpI1zGMOQFIXlvoTTHuFgYxupXeNhYDIJB68e9UhXaMqW0KbmO3yyuVCDbyDyPpUBMwQMZNoAztYZ/AH05pZ3kE+YmIZTkYXg1ZDbYcOiPuwy88DnHIFNF6pGPcM8zgDYrAtswOR7ZH6VA6zCJhIHjODwTkrxxgenSppTEr5xIQpYFAcDB7j3FQvdeUhCfOrnBZMnaPUGmjS3ZFRcZLMoJGASwwMn0qZ1KFRFgR8FlB+97/WoIY4XmzuJEgyDt24PTOKsxM0UgySjg/Lhclvr6insRONzpZZGnSSJg6MAcLjg/U1neePJKciQEg4PzCt0rEGO4KCpztySKr3FrHJIsihWA6bT1HeuZnbzpaNHK6rYpd27pIozgAr13Z7iofB+ptYXL6ZfEgpkwSE8svofUj+VdDcwbEcLGGHQlTnb/AJ9K5XX9MF2N8X7mZfmjkzj5l75P8qdrhdSXKzuTdpNCz78lgQWb1pbe5VwuCQcArxn864jwtrpvYHgulAu4vldCe/8AhXSaTKHkRnSSPI549+9TYnk5TrYLnkeX8sg4OO/0q5qdw4iUKN0hxz2rKUjzMgAZ4AHX6/yqw05K7SVL4IGO49aDnsrpkTYFyqhiCcgjp9QTV6PMZXa+4A5ADdO2B61lJfPG7RyBXwc5POauRuBiIONw6k9z6UFyuX4VaSXMnzM+cjHT3qxKvloUAyTyM8k/X8aq2R2MVR+Qece9TrNIku50J7en400YNu4uwKWDDLNgAk9/88VP5yxAM+1ioIAA6VUeTHyxlcnJJ69OtOjhMqJ5wYOVJBx0+lDQ/NkpYfKVD7m55PWpbmSQwJuHzAAcHrUVorROzSFmQEFd/Jx/9cVcU+bEeSTj696dhN2ZnKX/AHmdy/IAc4wcdahYpMWEICSFcYPJHqOK2JLPgMg3IeCCao3KR27ZYqoxgheh/wDr0mrFRmnsUorch5F2Es5IUgcn39q0LdAwDPlsDBzzx9KhtByZI2O3JA5yD9e9aSQyO2QR5Q5wRTQqkiGeB9pKqoOM9DnNVrY7n2ljsHy4I6jFbMUBwyHktgnZ1FV7m2WJiYSi9BtxnNFjJTT0KSwfuy20J64yRmsmYLgoC+4noeOevNbk2WDDc2BgDjBHv9KyrsATZj3vgDnGM0WNIMypJf3sayxsUPRc5xx1PeteAGaEFVQgH7mOp+tZjW4eWNnaMEcEbuGHtW1ZyRx243puwuMAgfke9OxVTbQQR7OJMgE5IIGD7U7CGMDGEwOe65PrikuCZSzqGRRggrzg1VcsziNndScHag6/X1pGaVyWJVePBnKgHIBbtUpthNG0eOSMgZ/zzUPksTkYXafm2r196fLI8TKVJOe5GcA/ypA/IrvYKkm5lJAABPJ49KghSdsJwiZJ/wAP0q7GQ85Cb8jPGM5P1qyYAqgj+EAgE9D7EfWmNya3Mtwq8A8AHnPJ/wAKlsJwJtkhJwBtIGfcitAhdiGR2O0cZPT17VnPLGXO0cDkHGBQJPm0NWG6jbjIGR09P8Kp6hLEkcgVm3ngAjn+dQQIdzFY9zAckHgVE4cuXVSy54U5FK4owSYlvO0iETIBGpwQox07mpJ7gkgQLyByCD8vvVA25EZ8tCGA3HJyc9hVy2j5Xec5GDz049aZo4pajrWQyOy3GF7gAdM+5960PskRIEB3OwOcdV+ppptowYySwPcAc59jVN7vyYWErnLE/dHQ+5pmT97Ys/6q4dSoQsMbYwOQKjuD5WXKeY3U5yQPyqG2lLookJEhbnoRjtjHsanuAVLK33W/h/hI/wAaQrWepHbNkAO4JzncpyfTg+lPkhURMXj8wAkeYSAfx/Gm26+WVcBiu4lWHsB+lW5GkRXaWSNhJgb89OM4GT69c1SJk7PQx7yFWwFL7iPnYnO5v8PpTZrJFxiTGCPlC/Nz1B7VpTtCkbktkADJwTgf4fSs4X0Sb42jVZc7l+fP4H8KY05NaB5bRRNK8aoD0wOmfT04rMuY/MiVYV3MG+UEnIz1zWoZw58xVVV6beSM/WmF5iGMa7F25YYyQPUUwTa1KLW7RqhZGdeQ43dR6+1U7+FFTdGd8Qx2HX8OorQvJ9iK25j/AHTgEbvQ/wCTVJrrMTu+Pl+UcbefUHv9KoqN9zKngiyscxYzls5B+Uj1+vtVaaJzlirFFX5Vbac5PStqOyWRZZWxuf5TtAAB6/gagaHykkPlcBOWPTcDyaZqpFOwEtr5pNqJd6YKum4DnqD2+tNMbFWCt8jMNyqcjPTrWnsREVYmDIQFzwDkjkfSslWdTD5eVByHCj0P60X1J31OivBCZBCkhCnJJx81I25EOADzgHOD0qKZS0xcgFcnLd8Z7VHdI6HfAwMZwSzn9awPQcLqxXmhaUsse4McnA6++apXJZonWcKwJ9O4rTaIBkfaxZTkk8kVXuVBeQFcxHnK87R1xSMm7M861y2fRtUh1O3QiMfLOo7of5kV22hymaLKSBiygjnGRj1rJ1+ISWexo8qowOORWR4AumhvpbCQ7mt+VyesbdB+HSmW3eNz1a2kkTGclgPXtjjFVbovCokG3GM7fQ+1PtbkQ2/mZG3kDjO2s+a6SafGDgcBaVjng3cLJ5HcNIuGzgAc7vY1qNcSKRlGXcRyR0pluQI1Zl2HJAA71PjzWyATgc0wlNNli1vApUF8ZXo3T8PenXmoxMkrK4AGAUzyTiq9zaq0aqSY/TA61hP/AKPcxo7Fh0Ck8E5600hQUZO51WmXKtgvwFGB0zWrF84O7e0bHardCMVz2lDaRhCWfk7ucj0rat7nFysZXao6kNkZ+lFiKm+hsQ25IUdVxyOgxSxlYZtsbgL27554/GkEuTlHH0PUf41nalckNGqABiOP8adrHNG8nY2JZUXKFvmPXHOKx7pgXZJCGAy20DNUpJ2eLMDFWPUdT75P4VEs/mAB2/d4yXPdvSh6m8KfLqSwedbzyMzbojk4XuTW5aXDspJYAk8AAEetcxgvGzq+xQuHbPU+9Wo5ZAiNE5LADBPUduPalYuceY6ia7SKBiuFOPXINZM19JJcBAykbckr3HrUWWuIwjMOQSMLyeKqu3lqVjAZQcAk4yf60zKEEizcsuWwzcDkk8CqE7PIp8tmVAwO48Anpz6detTiUOzq6HkDLN0PtUE7bp1RgVRhx6UjWKG2sbbW81ix4IcDI45z9e1WY3DZ8kDaPlxjGM+lJbxYkLckfwbTgdOnH51et/LVuVUZ4yecD6UMJMpyLLHIHR/l4UqeeRSIJDMS5JXIye5HpirIixvBwBnK5Oe3eq7OUYEj5Tk5Hcfj+NIm5ogq0YLNgADt/OmyhVAUHOTwB61VdwMgIckjgnHJqJXuAn79Amc5I6D2oIUR8OI5izlzu+7zwMc1KkjEvlWbJyV6H2xUcYHnbQPMC/3lx171ZjjCRYDsxJ64pA2ircT7QFiBBGMgjqfSolVTtZlKH+6f4R/k1NekrtQ7VduR+HcVHG2SCNxIJ3Afwn/OKdwW1y4gYqmeMDlQOvv9Kgn4LFd7EZyB0AqymXUJhQgGMf8A16q3C+UG8ndsJ5UHOfehkp6mdcSDlmGE6sO+PapVukBDhTjjBxj2A/Soo2EkpRlU4wc9OP6VNLaB1T7/ADyRnrQaNpaMknvD5TBjhcdOpHpg1jTIJceUGGCSMdvXNaio8MRJCYPZsHHas1It8m5D8mMMOCDTSCDS2LNlJ5UKtlRxwmSOfXHY1opeDYEAMhzu24/i6dO9ZVvBskc/KHHfcMADtUM7MMMjOFBwQpHAz/OmKSUmbkcgiywzu4BA9TT7otLI7Sswcjkg53H0x0rLgYRwvv3HndjGSQahmvfIiY5ZSDypGSB600Zcrb0LF1KriNFjdVT7zDnJ/wAPaqk0IlUsxj/etyO+frSQ3MkzAo5QEjC7MAk+uasxk+eXD7FJ4U9yO4xTL1iQGMRQ+UsTMFOSd3ykYwR/9eq7vsid1YgN8uxTuKj/ACauS3AWF1j3FWzlOuaz7Ys376XKruA+YcfQ0DXdirArt8zMY1yUYDn6EU8xfKyuhRWG1ix4z1H0FSwSlZhiI4LZ2gY4708uvnbXYj5cc8Y+tNEuTuUViB8wF4iSoCjrkZ65qC5URtgFo2bhXTnJH8hWuqLG7K6MGYevJHrUVxIrshb90yg4LDPJ64H0qhc+phT5EFwsqBnyu1kIO0+vuKqpbHzw2XxkAkjOD9K0JpGt3iZAHQ5DZHQdjU8Dq8gKfIuQSuc/lQjRyaQ+YO4xIoUr/dXGRnrmkjujLH5fAwDkg/5+lXpXhSWVEbluBg4zWVOgil2xudvXd2FYHqpqS1FVJYbyNkfbEv3lwCW49e1Q38TB5ZA3BwSo9anEmJicjy9mNrA5zVa+R9i+WSFI3bvX1FMwkrsxNTZpoXH3jn8K4jUZzpWt2eoxEiMt5Mp/2Txz9Diu4u/3YXexUZ7DFcZ4ot/MtrmPJKOp/A/55oDl0sekWVwXUKrBsjqO9Kjhbxdo3MDk8cHiuQ8C6j9s8PW0km4yKmx+cZI4P8q6BLw+YAuFL4z/AIUNWMIarQ6S3YbmKcLweeBmtDz1ZRuYjA6CuesXbbmVvLIHB6j8q0FcbEJOec561SMZrUllmMgO7cW7fNisOeci7BUdBgKB09602lV2bKqFxjJPWse/VfNVkwCME7apIulJJ2Z0GklBzvCnqQeTW3BdxhSV3KxyCWA5/wDrVysF35WwMnVeeelWVk8xixcA/wCyeKdrGU/ed2dBJfIjctkntnFU7u68zKo+CBgMe1YWpzErtJbOMgr1qG0Z2TzJNxOM7emfepa1KhFJXNjD+Ynmkg9Mqeta9lYNuPl/d9xjmsO0mWR1G37vOMcnity1vEijJUFiAePWqUSKtVrYuXluwtjsxjGPfPrWSv7mVQ4G9hhiG4I9D+laM9+hQcAt2HtWNPLh/kPXn15pNDozbVmaf2l44skgs56g8D6/hUUbrM0jIRuHA3dPqB/npVWOcSKiMDk8Dnj8KtMMEqiqGHAH9M1JXMkWYXJUQyKVyPvdM09rBzb7w4IOApbrx6VXtWaWbbLkMO/ofrW3CsYQYBCgcKf5mqtczlV5XoRW1mqlTITG3dlOM/jWnBBCkZB29MsxHtWczbXzjKKcYPQ1LJMVVCGwCO3p6VNjOU3LqPmhLgOEIxwNoH55rHlkYShXjVsnAAPzH8D/ADrQgm+cBiQQf4hxTbgJMwIG9s8Y4yPSlYcZWepSSX9+pdFcfdwTn8/WrzMrqWVsgnk4wB9az7ZJE3tkhgcKQcGppJEjhOc5I5XH4f8A16LFvV6DpZY+gOEBJHGA1MtrgyKERj9O5qK4vVkgUJtkyvDL696oxhkc5BUEAA56e5pWKS01NGdlWNnc70zy7dfoaht5UmV2VxwQQSMAVm31wo+UtjOQeMj61Sgn2SblQ4JA+ZcAfj/SixahdHURXoZx5YDFR1x2/wA96jvZ2MJC73AwWb09qwp5j5TtHkEHdx3PpioVlLzIWBC7R9445piVLW5u26RMA+/aQcDgYIqRpGjcKxBfkdOCfeqEVwhkycENkHtzUlzKNoA3Dj5Sox2pGbTvYluJWZ9vmINp5I5/L3pIXjU79x2kD5QvGao7SXLStwMYHFXLdlwCT8vXJOM1VglotCyY4igKEjAI6/zqssSvukDFj3TaMA1LNLuTYgXbnPI61AdxQhiCwbcu3jaMetFjNXI3VhH5yJiPkZYdT/QVj3EioW3FlkYcY9e3vWhfI+A6/cYYPpWVHA5dnYBpRzycYNBtTtuy3DMgVGlcs4HDKc49uasSy/OjIxww6HJH+c1gTo25ssoz/D/D68ZpwedcSB2APUjjnFMt009bmyX6qAhz03c/hVyzBY8oxGcY/u1z0srKVCI/zIdzFh1/pVmzvGCod5dFGCV6D6nvTuRKm7G4AkSnoCf4+5Pt7VTuGwdrAYU/3uopwkSQNhtwAz8xPp24rNuLpI0dJQpGckgHpTM4xdy+7sqKQWBckAe3+e9U5d5lP7xfLOT0PQfjWPd69bwMq7gJMnasgwOO+f8AGptMnS8TKuHUqXHPQdM09GacjjqyaVwVDvuZum0dR+XbvQ8mHjJXALDaR/npTcYcsmIymMcZH596jkMpfPzcDaG+9jPWmJo2tUt4ra4DKvy7ixYH161mtIWPysvy87j6ela17mSMxnO4Hg+orEe1l8zGAcjIx0A71gerB+7qyxIysSxwrddoPQ+1Vppg8aKGLFOMinXERSQ+YcMRwapNEY1DRj5V/SgzaRBe5ct+7+UDH1HrXNayEMJz0x+eK6G9csp2sGyAT9K5zV23AkdOhApoS2MD4e3ptdX1TS3IMe8XEZPo3X8M16CtszM0ifeAGRjrXkNrL9l8dac4JHnI0LEHg9x/OvZLYiKHawwM87a05bo5Obkk0iRy0ESszBiFyVNMhud0PmFtoYZwxqveXMcoVFkyT71HIY1j8uRgcDI3elJRKb01LE96vzDfsZeuapSamIyVD5JHTsM1lTyxvI+SCq8cd/wqMurNgy5zxnvxWiRSUeprJqMiAM53BRyAP1p8GoylWKjaWJwc4zWPDdQ+YSXPXoe4rSSeCRNiHDd8jp707XIk1HoadtfCR0ErAtjlWPb1rTjvI8LtK7c7Rg81yjyxQzB1w3YjvWxBNEUB2kEdsdaLGM2t0b0VwWyRtwOgqF7llX5S+8Zzn0rOj1CL5kHHTvTpryJxtUkMB1JosZp67F5L4tb4z06seo9qaLoqy8EpjuaxZpWwdgJJweO/qaqJczHIyQM4BPap5Tpik9js7a5y+Qdq9R7VfW5IlGPrnOcn0rjLfUBCQXfYOgwcg1fg1RCu4MW54A6D8KLakSgzuLe4j3LgcngVZW7X59mTjnOea5ayvS8YOTg8Y6flV2C7jcsS2T9OBQcjg0bBu4o2y7sW7Z9ahm1ISsUTJb+8p4NUS4mzuBVemFqOBEzsXnnqTU2LXKty9BN5QB3fKxx17/WgXQXCD744HbjvzR5e8DJDduaz7xikoAPAGAD3ocSoyUmXbmfbtw75UgYA7etRveMerKy4wOf51DCIXTzWYFjzwTVeWDCOPm3Nxkc9e9S0aRa2ZJHO/mbQdykbs44P0/z2p7TrKDlsAnjnODWdKskKqUcnB+6AMfWlgbcw8xpCpOeg49s0rGtluLIW3Ikci4L/AD9+D/WtPT4w4KyDk++axrxgtwjOGRe5HSrVjelrjaMuR8pXGDRYck3HQ1pYlGMjknJXHasW+Pkzsg3YI6j0reBGxS+DuyBz0NZWpwqN0iMpI5ORyPam0Z0pa2ZTg1BLZlG1mxgZxnA/rU/21Z23rIxGMgdP8/8A16xLsvGwET7gzDgdj6Vat4ZJCAxUKeCMD5T6e9I3lCNuY1mkLRgZHByfcU64udnzpjeOABgCiC1aOIA/e7cVSvmi3F9/z44z609jBWbsXYdSTCmTG8nGM5z9KuwyPIJNnQ8Hjp71x9rE0lyWkfPHQV0ttO0dvgrlvRjjNCdya0FHYku0ZiWwee1VwyBMOPmz07VM8iyqIwR5meSDwaVRsICAOMYBNOxlzWWpCbWGVyTtznBJPFMuIFwAFb1XHJBqSeQxLuYgHoeKzLm9ZUclVyx25B6VWg48zZTu3aMsNxDngg5JX3pq3RRTEgxI3Hyt0z61BOrzvuLFiRngnj2NSQWH7ze7bVJzgnJPtU2OrmilqXrOdzFBvdvl49v/ANVKYmlUqjZB7DqMU0GJljXcoCnaQD1xVeG5MFwwyuOw+tVYyvfVEN1plvcqktzHnaQCVbr+farNjZx2cbLDmNQo299w9amVgY8lstnG0VNAnlLvKjPPPYcUJClUdiFyUCKISTz+7BBOM1YtkyBk7S7Zx3P+FV5ps4bA25wPceg74pI3kEoLDDMwGF9Koyk7o2Uu42kK3MQBbIAPQnPWq0TxpmSPhc5xnv6Cm6isoljd24zwAoxn1qh5r/vgEfeMnA9+9c567irXQXU5nl3RJlejA8HP+e1VpgVBwrGNvvHPT60iXRjkfdkbjk56/wD1qq3MzhMxMQM5IPOf8KDOSadilfsqOdmMHpz3rn9SkHksDxjqe9bV9hrdZSQSTg8dK5jVTtVxwhHA9waqKC+hwWsXP2TV7C6U8R3IOR6V65a6gJYFLNlXGRivEfFzYSPaMYfI/I10mi+KDLbQQxuWm2j5VGSD9K3SPPnNKq0z0NrgqyrsPGTu6ZrOvb9zJhzzgA57isiIarermCxu254coVAP1NX7fwd4hvU3MkUAJyfMbcw/KkoPsa+1it2OhuVbO3aO3J/lTLmRJPmVwpAI4BrWtvh9cptW5vyGHXYgAzWnbfDqLeDNf3DZGcBtox+FVYj26Wpw6+akhIJH9av/AG0+SCFcvjJPQ13kHw+09hkGc49XPpViX4f6eFxGZ0OMnL9KLeYpYm+6POYdR2uGZiWznDCtmPWYpFCtgnqMdBWjN4CDS7FuZMHoCAe9Rt4AuU3/AGe8Uqp/iT8qYSlGW5VOqQqAA3z46d6WC7dpBt2lfXrVefwhrETNiJJSpxlWwSapT6fqlqzCSwnX12/Ng+wFK7BKPQ3zdITwSpx3qVZofKG5gz56enrXLQX2wsJ96HOPmXFTC+iYEiRGTvg0XC1jp3WKVEIZTt6cCpLVAJTK2MY25A61y51KBPuMR05x1qxaamoY85UjOM9KB+8kdInm728uQgA9Mc1o6fL5RO1s8/Ma5ZdZRduxsDvVlL522MrDbnkjvSaRLcmrM7i3ukJ27ioPvTmu0ik3cgdxnnFcZa37ROAxYgZPJ65q02oM6tuAIPQ5NFjFx1Opj1VZZCobA9AenvUd0yvu8sj1OTxXG/aFSQvGQGzxk/0p8dxPKeZAYx69c/WhrTU1jBJ3TOntbhoWUcEZ6A8CtZd0xDKykd8dhXLabJJEMy4ORknPat21lRY+HCgjAxU8oqkrPQ0ZrdGTgBzjnmls7eNUDDDgf3uTmqUF6u5tpDZ9sgVfF3sAVmwOo44pWM+eSViG9hB3/KAp79s1neRJbKGRhtGDk/qKvXV4qrwyuw6YrP1S6VIlzkMecr6UmjalKWw9tWhCSKThyeD6npWZe6iZAAzdO57msu8X7RzCeQcg54/Gq4jefILB9nXA4Jotc7YwgtTQDSehY4yff6Vt6ef3ceScnqPU+1cxA08JZduGGTz2rc0u6IMbSKdw6kmlYVbbQ3vO2gkKWXGKwtSkBlZhhcNwMcA1cOoqrFfLBwMY3dahf/SSNyqozn5aNznguV3aK0BVAAuWfsQOtPnvj5Pzg+YByo/xps1qIkZYTjuTmobXzQVEny5GSpAYfnRYq6fvFu2vXjkLSJJtH3B2NTR6siMC7YJb73YfX3qvPI0kbFpD6DGOK5/Uw/mKYgRkk9PajYmMIzep0r6qrxsqAE9mbpz79qpLPvmdAodcDkDr9K5mFZFdSeV9cYH0q/DfpbyNluvOT34q1ccqSj8J0Ecqq2SNp6YxVa4u0Hf2JzxVSLVo2wY22MB/Fz+FZl1Mkr7iNyk8qDTsZRi76l2a6USt5XyqcH5icD8Ks6dKZi0kiMQDjdnviqNvGBGytgnphj2qS1hdGOwDGc5HUijlY5VFaxuIFAb5BxzmjzUG7PTAJ3dazZJXVPncpjjHrUPnxvzK24HODkVVjmvfUsvcCSYkHgjA47+tKLgh1Ytgnjk9fesjz0ErKpxnqc8U77ThlG5WxjINFi2dhqcsk5KDOScFR1HNZMc0g37sx4yBxwMnpW5cwmOaQmIEEEZz71RlC7YnlU5f5Rz+Wa5j2XJJWMm4njhhbKbmzjd61lXU7MNiONoIOcVdvYmclWHyZx9Kx33xM6ZXyySMetNocUmiO4mKptPY7uO5rl9YnLb2PTGea2rwylQXbHbFcvqjDewU5UqTVxRjLQ4bxXJkRL2LFv0Femfs+aRHLbX9/NErHeEUkZP4V5X4ofN1En91M/TJ/wDrV9B/Amz+yeCI5CQDM5Y+wraDs7ni1Fz1Wd5bwx5PyjJPbpkVomDZH84wMc/Wq9su51XgEsCc/wAq1Hj3AFAzg52k1k5Nm7gkZzwF5UwFY4wB/OnT5V1CAHcMHI6VcEAXeuCDjsaX7OPLGTy3GQeppXGrBb7THkkAZ447CnTwknCkAkbQSMjHeiOAgEsCvP6djV+FY3DSLg7cg59KLicbamDJAY5WTkD+Ege1WoYlB4GADzV2dFnusZKYIbPBBqWG02tuX7oOCR1NJsbs1qZ62ali7cN7foaZeWIdyFQAryK1FQqWXg4+7kHj/wCvTpBtXnlV5znrS5mLl1OWu9HtpGxJBE3IPIFZ1x4M0u5OTZR9eSFwa7Jo2fcc8EcfWpAg3MfmyeM4qlUY7NbHmV38PtMLERo8ZJ/hY8Vn3Hw6Maqba8cr1+cZxXqc8BXaCSTnr6e9OkjBUksMBegHFPnHeS6niV34L1eFBJDNE/qGBFUDY61YrtntHZeo2fNXuF3CmGK8oWAAH61UFnEw+4Gz0IFPnRV3bU8Se8eLAmjdDjJDAiiHUlkH3zha9hv9JglgIMYZjnJK8Vz+oeENPmw32dUJP8Py1SkCkmed/b2U4ERKE961rLVUMQEibSOxP6Vt3PgWHZm3u5kfbkDORn/9dYeoeENXth5kMsVwpH8Q2mrTuDlF7l6y1FDIcEgjp81bCX67ADJnvzjpXn9yt/ZvtvLaSJRxvC/L+Yqay1JS5CPnBHOcilYTgnqd7BOXn/dvtz1HOKtm7lXo+V9SORXJRahwDIWBHUdPwqQ30igCA7iTls9elKwrNs6O6nZk3ISMDIJPH1qjJeM2BIWlLHHIrPj1dCuJgRtOMjpUo1G1Mv3lLAYCHGKVjSLa3RP50gYCNdsZ5z0qwgRIsqRn7zEVSe9iZm57gHB+7TLi+RoiqDHTPI6DvSaNVNst2lyrXONxKDgnGa1oJRJmMbgQe5rmbXeZN6uVX26n8O1bdu6MmGQg56jt+NTYKjXQ1orUQglpFJz361YwY4dq4Xjnn9KprIAgG4+oBFK8zBSGYkMB0oOZyb3ZWvZ/LfJIK9PXNKlsxHmeZ1zx6GmtFDGWIJyRkbv5VZt54wcKpZgOnYUku5TnpoVxaszNl2H04GKn+yiNMAptI5yev406WcZy5+mM4FVpJ9ysVJDdQaaRm5tkd5ZKcsBwB26ViXcMRbBIBx/Cat3V5Mr4lUkZ7Hms1YJZJGlbEeeRuPPvVpGsLrVsdDahDuU5OB1PX8aJxKEICqOfrmmGQRnJcnHRh/KmG8DMFQkhjn8apCcncSN51HVtgOQVPWr4vZFGdrBj0JHSmR3ESLtdOfTpzRK7MCxXpgfL0pmMpX3Qy4vJWVgw3E+nANVxL5WMrsJ5+bp70rSeWOu0ZyMDNVLiTzGwuFPXr2p2JuPlv40OCeQOg6Uy1vmMiBRjJxyOtVSUhO4pyD94HOaLaZFkXC4JbnPHeqSuTKSsexOxYthyoyRz/npWZ9mGNpbJ5Yg9CM9RVxXlEZXG0kkkkdaqXDYnRiRgdK4j2JX6GFqAzKVUfdyM9cVhXSs8gCnnB5NdDqX7yQtGM555PWsa6yiZb72eoPQUy4ysjEvn3Bkzyorl9UddmRkc46e1dFf7vny3zAce9crqshdjsB/D1rWKMar0PP8AWiZNUkXg4wvH0r6w+HtoNP8AB2mxMoVmiDYHJ+tfJsA+1a2mOfMnH/oVfZmixeXp1rCEGxIlGOhAwKrozyabvJvzNCzClQxJ3A5Oa11UlMJ7Yz29azkbDYT7q/LnOauI5QDnjd+YrE6Jaj2kVcIAv1Pr705YSu75u2RgVTMwMx+UFM84571f8zAVT97I49RmlcLWIX3+ay7vlwcZqeLEbpwoYAZAHQ1FMvmcsAmGJYDrj2pYtpjZvm3MT05wAKCnsOYp8zgnHOCO5FT2eCm1VbpkZ79On61UlOJmGNw69O/TtVy3ZliPyYU43Njp6YpIUtiG4RVaM7jkN9B71HMGlUA7TnPB/PNOuQWZmJGW+Yjv9afDt3EAY4Az7dRSaGnoNZfKZcAEkDnHH5U+WUKixkL0IOOoqO9lOAEAGAMkHHNUxKxZi+Nx6d+vSjYaV9S3Inmc4+Ynkf1H4U1owYyGXJIyccZqtMziYYJPGCf0qSOY9N2BtK8jmi47DLpEKkKBv6kA/wCcVCtusUeAc+pHpT5opAcDb7n1qZXz8vGVHzE9+f1pD6EEiHaFbrnr71C8KuYywHXjI9qtugYjKlTncMHtVd8so5wfvZ9eapMixUktwoDn3zUbxB1VVA2k4FXXTzFO7uBhR61AhKsrMCBg5yOKpMVjIvtOVlKsgOT6cZrnL/wrp13ktaqrYPzIMEflXobRl03HAB4OOeaznt94JweOoquZoSZ5fceC5ohvsro5H8MvIH4isW60/VrSRzLCzbeAycj/ABr2N4GUqp78YPYVXmslkVht4GeafOUmzxZpCj4kLRsOu7gU9Z8gI7bivC7RmvVn0aB02mEHPqtZ1z4WsnLbrRCCeoGKpTK9o0ef/amyyrIEUYzuPX1/GrEFyGVAkgbPfHvW3deDrIudsbDPTaxqs3g7YCba6uI27cg/oaOdMvmZatJkQB2cZHHPf3q0NWAVXaP5/bvXM3fh7WLVldLkTrn5t6cgeoxTlsNdKlo3tpVPHIIxSumZvudNa6wH+YqVYkAc5zRLqvmkspIz2yCa5OGDWDxPbbe2A4p0lrqsWWTS9w7FpuT36dKegrK+x1ayyOQVcMB0JPT8KuR3aRuTJJuHpXDCTW0z/oEsZ5yI8N/WoVutRTiSzuevTZjHvRoDTZ29zqgJwq5B7jgCqMd5J829/l9hjI9qxLWe5aVd9rdA+uzAFXkupN+TbT5zx8lOyJ20SNK2/eyEvwcDg8/rSzLGHISRQOmc859KroJ5SQttKucYIHGanOl3bkmW3fsx6D8aehLvfUYYIXiO5tzbuxwCPeoQFLDYhABONvp6Vox6fLDkvGnToT/hQYHBBMqBecso5/WhE8xTitsgDJBH8JNEkhjYAuB245p88QA+edyevGAetUZlwzGJSNw3ZxwKpWJ1ZBe3KYfactjjJwaqxXDsuVAJz16nFMllAYeYF45xkLmqr3WCQuMZwc8batEtFuWWNm+Zjv6cnJP9Kga6jikXyzzu+6eTWfNLmTLElep74qtNdqZ1ES/JuHJ7GqSM2fQe1mBVFOdxJDjJxnpVG6AUNuUjHY+hq/HIzuS7bskggcY57VR1FmYhUDbWzk9cV5/Q9qV+YxphGU+b5NmQMGsPUgq8hv8A69bV2yqeRhSMD3rnNSIZ2UjIH400NHO6lMNxGcErwcZrk9VlKpJIVx8pJI45A710V+v7x85zngGuP8QzbLK6OTnZtBPuQMfzreJlXdotmJ4Kt/tXivTIv70yk5r7GhSSGMbEJYKByPbrXyn8HLX7V4+09CuQMt+lfXkiu0CH7zHgkdBxzS6HmUXawiNiFVz0BZSeKtQIPN+VyAqk7T6/Wo4rc+TKCpYgYBqaSMiNsDOVAIA9BmsmdJVnhYnauOCAG64zzVq1IaRQCQME4HPA9f0qQYMDblyc5VfSoYJCJPKK45BKk44/zikyk7l/yog+4jJ29cfhSRDBdY2OcEMQOvfFTrIiwDj+Lv6VVtEJmJbIPqD6/wCf0qWShbkfMAJAgAzyPf8AyaQkLAcFueGz/KpZYxGq73G7AAA7ikUxGaRT1J6D19aB30KUhKxFnU7yQOR2pnnOGYLnGNzDOcYHFXbkbSRt3Edcjjp/kViz71c8gKBuJ9Rn0plRsy27M0hTd/CMnHFAjw67cMQAcDvxVS0BeUg7nIBIOelae0iMucHC8kevfFSW9Co+QXbkKDhc/hxxUcu4HgHoQCT9etTsV3R79p+Y4z1PNDpneAeMAn0x/nFIaY60uNwAb5SvJJ657mpfL8zyyPlA9ahtoliikJwWLdfr2q9FtEZEeT269KZEnbYjaIqDnjPXJ6VnsjGN3Ax1A9vSrdy7AKBw2CQPXHSqySg25XJHc8fypgiAlmnVRgJ3zUxQMrfkc+vpRlSU+ViBgEf1qa5Xaw5AB+Ugc/jVImTI40PIXAwN2T60xox8zsMY5z6ipYWZNqsVAPyjmhGMjMRxwePpQZlWSNTkjO7HB9s01Iwrcg7Sc9asuF44AXt9KVwcbj1HBNAXKT248xTgZx+tM8teVYAMfarMx+64Ptx2oZA+MZ3Y6jtSD1Me8gQOe+eelQw2fngsAeavzxM4DHgg5xjApYi0RDIucHpSN1toUPs6opWXJGeTVP8As9bcmSNCYScsAOme9dBO0cqqTgE9M8/hUClI1IYgEjAX2pC6GXJaQzLu2q0Z6MKa+mHaBHh4+yt1FXDbSI5e1ZcEgtGRw309KcJmj2qV2P12twT/AI07iu1sU1swi5aMjPrz+tRS20ZyQvy+h61pyzSbQOueeR3rMuJZS3zABcYyOoFUgjJsq4Uu6hOvGAcVPHHFjhvunHIBFRSLuUAspwT/AA/4VHGvlLtQk9gueM1STHKSsX0ERLEAevHFRzSxJjAG7sfast5GIO84OfwNMnlO0FpFIGSMNVJMwl6k8s0chwAGyecelVrpoVBZ2wqHhVXNVZb6FAwZlxnoPWsa+1FZpsIrYAHzD0q0jPqaxuctg5CknGBj9ahuLnaBuHXqOvHoc1hz3xg+ZG2jtg5FZdxqUspPzKD3JOfpWqiQ9TSvBGChAG5uueo9KzruSOOI/e3AYBIxj3IFVZbpj1ZiB0GMk1RvLx3JSPcMDIYn8q0SM3MS6uAhDeZkdh0/PvVFLp5Jk3dN393p61XkZd26aTcT6c81D9sR5kA80vkcE8dauMTOVQ+nixhDJIc4/iB7HpUU14qLknPy469KW4VkeQSRnaec+oz3rHmIXflT04HrXlH1DpqRDdMZHAbB2joK5/U43AYDBPt6VtOG2twD3x7fWsq+QbXxkA1SZLjY5LVgRuB5yMYrhfFL7bCQDgM6r0+p/pXd6oGVyo5HpXn/AIuwtpEvGWlzj6D/AOvW0djhxekGdB8AYTL48iZQMqhxmvrKABoWJQngZJ6c96+XP2dEB8W3UmMskBwMZ68f1z+FfUKFgqxNkMfulep4oexwU1dIfHgQxlDujPAU8ZapkAFqokKbWb5uadBE3lbeG2tnd17cGpIEQFQYsKQXYkds1mbXM0svmylFLtjaAD2HFPRWeYh4ySWGO2QO9WTCkcu4j51GVx0xVlQquXKbd4A9ePcelTdFcxDHIXkI3E5bbnb7dqliXZKrOF2AgZx3qIxYcsg+aVjjA6dqkf8AdKiu28c98dKQXHXALTIBtVQce3T/AOvVKZihfykIIwwOcHirLT/KS23BGMA8Vn3V3vJZG+TleueOO1A43LIkEnltj5RuOByapXis9ygXhsYf1HpSBEUtGWcIASCeP89qYpDYCjLFj8xyd3A/lQWtHoWrbLKCF78cZzVqNdoOxWIJzwfyqqiOsjjngjbz/I1ZjJhclGyXOATxgf40mJspXBYS4jUKOBjGQe9WZYN8G5cEuc/XikBVZcn7v3snv2596fIf9DIYhWGQOfpSKvsQQjzQBgYHQt35/WrKSiOPjkrnIB46dBVFpWBLRnlQR06nNSuwWFywJOB93nimgaIizNOzbcgcehpxwlsOcMQMjFRqAzyDDEYBzjvjpSTsAectjj6+tMH2FTLsRkKc/Kc8U27lEaIOQFABzz9acJQkYyQAGyD1B9qc6K6kk53dcUyOupEjghmU5GOQcdfWnFigRomAboRmmmPaAd2EbjHbjoaQod2VO0dTkZB4pBZDnO4qRuKjI4/rVhQNu1+hG3jvVRopPKXAYBfmYjqRU0TEbVkwRxndQJoYyMDsC8/yoAZFAUgccsRVgsrlSSN4OMilkQDqed2eRmgVyqwyBj5VOC2e/rVeQeXkg5UcjHpVqeP5QQcYBOP6VWikG/aPnUjOCMZoKi9CpMqkFlBUDseQaqySZTLLyO/U1qzggphcqeM+ntUE8aMMoo3dMY60rGimjPiuWt3Ck7lJ4Pr/AFq680U8ZVtrKQTz2rIuoiAxHLfyqnDcyoxUbmXGMlaCnBS1RsCPCH5jgH1zWdd28xLbCCh4xu60wXRLEDJGecdcUNeqIt2SBnnNUjNpoyruSe34ETY788UwXICHcxAHIyCc0alqY42qw7g56GsOW9ldsRkr2wehzVobhzI1WmVz8jbgRyDng1nXE4AfIPlk4wRjFU2vXhX5uGPt71k3eryu2xmdfmx0xmtYmTpssT3BlLNGXIGc4FZM07ohZTwASc9RRJcSYzkAN0ANV3lV2G9hnrgVqkYyZEyzTN5kikAjgjj8qiyYM7/vAfxH+XrVk3DMx2gbenSql467Bnk5zWiMJSIZbyWQHGQCeo7D0qEtJkKqAseBk9adGgYDaDjv6VHJE4JEeMe9UjGTKlwoTLsF456dKqR5kuIymMlhgVPPDnmdmbvwe1OtWi81RGNx3ADBPrVXM2mz6m1IKyu4AyAPl9q5+7YkjC5C9q3L9hudVzhjySME471i3YWLLEgg8jB6V5B9hBlWUK2w79nHKisLUAQxUrkZ3ZB4xWtIcRMwHzsM/LWRLI/zb1BDDGKa1Haxzmq7Sw9H6V5z4ywEthj+Jv5CvR9YKgbSh56E1554zUeRA3pIcce3/wBatonnY1fu2dh+zhI6+LZhFjcUB57jNfUNtIF5LHdztK8fr9a+T/gFdLbeMju6snFfVERiJQqMDgfhTex5tPY2gpQsAPlJCjnpx60oC4ZQTlfkwT1/yaoW7qNgbjAzyORStd8MHyC3QZ6HNZM1SZci3CWTae3UenSo4yAw3nDZwCD9P60gmXagyOflGBwT1qnOzb1UHbkfgef51Jolcvu24LsHzbsAfzNQZBH7srtXLAHk9asNBuQo3yspwNvSq7x7X+Xhc7GDAdDSuCsUpneORwrMxC9Se5qpKmEZNxLN8g74JA6CtG8gVTG7n93liSOv0qnMhlZMMUKuc45OBj+tMtMsww5t41ckox6k8/jUoiERBOGUAtjP4VYjMe3jAwCN2P1pJ4AyqFOCOQRzx1/wpNk31K8j+ZgjGW4BA5GKRFdoCWUkgYzketMjjecMAVDgnAA/lU4QouFGBwo59ulTcrbQDGTHkknjLcZOagudwVAgPzHGB1Bq0uEiJHGQQccc81nPIWzGCVwPlP8An8aYIkKtuYnPDcnpz6Us6lxgEx5HXPp2qjNN5ZEZZSMDjPfHWr8MqyW4TBZwfl9hjmnYd2tSVVCYfbtUDOOhqpNulViuc5wT6Vbkxwq7iW4BHOOakjiKgmQghlzkjqaojm6mRcRuYdv/AC0GSpHH4mordyskcUh3ADJz/EevWrt5GnzBCSSAvAz+VMiRZGXhsgjacc4oRd9C1HtAXnIPbr60pOBuUDC5J4xUcB8pjHgEAkDcOvpTHbBkKlgduMA++MUWMupZQgJtbg9/pVdo9p25ycZVsZ4pyE4QJ0PBDdqmkPyZ/iDcc/yoC9ipuCh2GSyjDADrzSGUs4Aywxyc8fSmeU8V40u8lHB3Ke3vUMsu1gqZUDlR2PtSKLzyh1OFPy5xg4NZ0g2SjJY57Y4FS+c77XABwPvDsKT/AFm5cLgdTnrT3JT5RGcIm4oQvU4NU7h1cZj+UEdzUsrNEuANy9Oaz7lonQsCdyk8ZxRYcdRJH+ch1GDzyev0rPu1jeXKkrg568GpYrjcWR84A+97etMuPLaMn7zdgTijoaX5WZs9qclwzDPAbOMCq18oCZIz7A9KvzyPFxtB47mse5kkdXCgqOhwcEGqSsPmbM27dGLrk4Izz3qtBKiOxZgPx5NaLQNLjzBuesyW1YTY27ge4OMVaQOSasSXjxlQGTOfTqPesm4FuwOI93OBwasybX+WNiUA5Hp9aGKqjbCADitEc03YyLqPfkxjYAAKzpE8uQAnPocVsXku1sABs8g45qkIzuLYbcTn0xWiZiyvFAGLkE46k9qbdQoTgDcQOuevtWk/lqm1sZHNZ7bi5SMZB7d6vQxd2yAsEUjhQB1FU52JGVBKZ69zWgIVVQCFJH8PXFRNHukwvI9cfoBVXJsjJaCR2Znk4YfdH+FOjhMDpjAHGBj3rQlKqI8AAgkA+lQg+ZOhz0Yc+tFx2PpS/g/0nJynUkEHJ+lY80btM8kqNu+6Sa6VY/PuB5pHyEjDcnHoe1Vr5CQyhVIC4wSP85ryz6P2jWhzlykccTApgY4HrXM6ghEZwcqvfpXVTjenz5z0HpWDqKKWOOB0yKaKjKxx2rYbBB6HgZ61wHjAg2acHPmjn8DXfaiN0jAcMOoNcN4wU/YD0x5qng+xrWJzYz+GxfhJcC38bWTHkE9Ca+s7R5VcbMlOMkgHHFfG/gaf7P4p098gfvAOTxX2DprsYQrNubHHPtTex5lF6GxFIQAA53tkH6f40JCzbtxw2cMx5x9KohssztkbT8pH61djmKoTnIDDqevFZs31RcCsS4GQoOOew7Go4zmZSyH5cnkZHWpImlbdG4P3cnjvQqyKCTtJ+6RnnA//AF1DY0ahdVWMH73TGcHFVbhh8gygBGT+tQJNkq+CSMjJ6ULudSyoS2CSGOOMdqTBRsMV1mdkI4Veu7k8jOKhulThoydvLehAJB9qfEjFz8zLv55PHvUs1uAgJkY4wAQOo9cUXK0TI4C5ZN5AYYxjgY9/zq220qEYZyCevv8A/WqnbAvIQ5AIGFz3zTzJtcMikR9M47Urg1qSxhxKANu3kcdzTnKqGJKhe56UseHYbm5IwM8Z9qguJiVPzYbOQAOaYuoMB5eOMLkDHes9w3mb1YhGB+uQOlLHNulSMK2MHJqdo8y7iBwCxAHING5Wxn3ECMVYAgseR2qRZfLj2klSAFDFe/pU0sbSMpGQexHT8PSq5QNIFc4O7JGOvPWmmVvuaKJ8i4XGCGIHQVKGZ3QY4HOMdeaiiK+W2CCPvHsPpU8TNu5/1Yxtyaq9zG1iO5QeWrnaA2duCOaq2ikyEMenv0FPuHA5yQqDv2H/ANeq0cp5HKvxkeo56VPUtK6LNzEzRh1O11B79ahQs4DEDC8Z9RT1lWRAjDBb7xY4Gee9NERiJ5JRjj0z7+1Xclqw8YCgNnp0PNOJPlscFu24dvpUdzg7cNz0z15qIOw3q2cHqvpUvcSV0SuDIOTt3HjPQ/T2rMubaWRzmTYytlGH171cDFCIyDxzk9vrUEkscKPK7AJ1znp65ptdwTaehWlZkAG7BAwcHrUockqy5C4xwc4qms4uTuQDYc9D94eopd7JkZwehWmtRtdGWLt0B+bABHPPesa4dCTkEAZPyirNxJvB4GMYx/Ws0iXzQB1+nFDHBWGuGEY2Zzn9KryLJICjsyn2q4JlQkHHA71BcTAuNgI9aEinJ3K7jaM7gy+uKqlMSs/UdevXjrV2Up5KkD5sEEHvxWLc3RSVYlB+b9BWi0IV5bC3Cn70W0gjIzzkVm38pMY8sHnrzg0XN0LdMllBrKnuw6hnOGPOe2KpMfK9yyzIoyy9ffJxVG4kL8Qrj39BSQo8snBZoxjvVtotkY24FUjGWhnpFt3s5+frnGaVowUYKDn72asuhDFstkDscYqu2MkA8dOveqRi9Si8e4YySM7j71Cse0grwAcBu/5VfKlSC31x61XcfMzNwBzgnFUiSN3REYJgKehH8s1nzzGRisQ4HRuoqztLL8xxGOT3/HNNKhsMc4yTjGDiqRNkjNkicsQScnrx1q5YWoQxscBdwxnvUksQXLZycHpzVywdJGiEhUgHJDf5/SqiOWx9JzQuWldyvmHrt6HJqhdQEQh8/M1FFeWe8zHnikJbDLkLjnpXPalEyM5wnNFFMuK1OV1fT2b95lB7Z61xHjLTnOlycplHXnJ55+nvRRWsTnxXwM5LRLWSHV7OQlCFlXgE+v0r7B0QO+n278dBkk8kkUUVp9k8mkbH2bcpLY+U0GJgoKkDnn60UVgzqiacEbBNwb73JB5zT7cAoG2je3BOaKKgGRSKxkDLtA6kVZjjzG74VTngDPFFFA2MjUlUPygcgYHXHrSMjFjyMDj/ABoopIBmOQAowe+eTjnNO2ERhM5yMg+lFFPoMiCuXx8oJzj260wqZY8sxJbjPcEUUUiiiYnSViNuG9yD61fihby9xIPAPX2NFFNDmOt4dzOSBjsM55pxixMG2oexzRRTI6leNGWUFSAQQv1q0yBGjJG4t93J6GiihFSILyEys0ZwM9e+OcYHtVOSCSP5d/CsADnnpRRTEmTCEKxJG5OeN30/xqeROGxjj1/OiimjORVCtO+GCqOvHv8A/qqN7c7TuI4Yn1/WiikNMaI2aAruGSODj0rOuot4ZSBtYcjPUd/5UUVXQcdylaW4h/dRj5dxwCelXJoBlcgHdwcnvRRSWg5u7uQeSxB+7nn+dUHt2R2w3Xnr1ooqxJ6mQ0Mwnk2SDH3mz39AKltoS3zNt5GciiilE1qbEdzasuSrDntWXPp7yMSrqrYz0zmiirSMYyZg6laOxwCoydue9VYdMZ4SzuGIJ49aKKuKNJN2Jzbm2UINpUHIprRSspI2YxwKKKZzsSW3kEAbeMY6Z/8ArVS+zyB2YFNvHH170UVTM0Si1dR5hZciqt1bSs6BmTsf0B/rRRVGfUj+xv8AM+UKcgA+tVDZysV+ZMnjOe3eiimC3A2kuQAygKex/wDrVN/ZsqldroBkZA+tFFPoPqj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutis marmorata is a normal reticulated mottling of the skin caused by vascular response to cold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kenneth Greer,MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1490=[""].join("\n");
var outline_f1_29_1490=null;
var title_f1_29_1491="Bone density testing";
var content_f1_29_1491=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Bone density testing (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/29/1491/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1491/contributors\" id=\"au7911\">",
"       Michael Kleerekoper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/29/1491/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1491/contributors\" id=\"se178\">",
"       Clifford J Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/29/1491/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1491/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1491/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/29/1491?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      WHAT DOES BONE DENSITY TESTING DO AND WHY IS IT IMPORTANT?",
"     </span>",
"    </p>",
"    <p>",
"     People tend to think that bones are static and unchanging, but the truth is that bones are in constant flux. Even as you read this sentence, specialized cells in your body are busy destroying old bits of bone and replacing them with new bone. Unfortunately, as people age, they often lose bone more quickly than they can replace it, so their bones can become porous and brittle (",
"     <a class=\"graphic graphic_figure graphicRef53181 \" href=\"UTD.htm?23/45/24275\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If left unchecked, this bone loss can lead to a disorder called osteoporosis, defined as reduced bone mass and poor bone quality. The disorder makes bones weak and prone to fracture. People who have osteoporosis have bones that can break with even the mildest impact. For example, people with osteoporosis can break a bone just from a minor fall, such as tripping on a loose rug in the living room.",
"    </p>",
"    <p>",
"     Each year in the US, osteoporosis leads to 1.5 million fractures, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       700,000 fractures of the vertebrae, the bones in the spine",
"      </li>",
"      <li>",
"       300,000 hip fractures",
"      </li>",
"      <li>",
"       250,000 wrist fractures, and",
"      </li>",
"      <li>",
"       250,000 fractures of other parts of the body",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Fractures of the spine and hip can lead to chronic pain, deformity, depression, disability, and even death. Plus, half the people who break a hip never regain the ability to walk without assistance and a quarter need long term care.",
"    </p>",
"    <p>",
"     The problem is that osteoporosis does not cause any symptoms, so people do not usually know they have the condition until they break a bone unexpectedly. That's where bone density tests come in.",
"    </p>",
"    <p>",
"     Bone density tests measure how strong the bones are. Healthcare providers use these tests to both screen for and diagnose osteoporosis. The tests are important, because they can alert you to problems with your bones before you have a fracture.",
"    </p>",
"    <p>",
"     If it turns out that you have osteoporosis or are at risk for it (known as low bone mass or osteopenia), you can take steps to prevent fractures. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHO SHOULD GET BONE DENSITY TESTING?",
"     </span>",
"    </p>",
"    <p>",
"     Osteoporosis targets women much more often than men, and it becomes more common after menopause and with advancing age. As a result, healthcare providers recommend bone density testing for women who have been through menopause and are at least 65 years old. In addition, there are certain characteristics that put people at higher risk for fracture, so healthcare providers sometimes recommend testing in men or women younger than 65 who have one or more risk factors. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"      \"Screening for osteoporosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Risk factors for fracture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Factors that increase a person's risk of fracture and may lead to earlier bone density testing include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Cigarette smoking",
"      </li>",
"      <li>",
"       Long-term use of steroid (glucocorticoid) medications such as prednisone",
"      </li>",
"      <li>",
"       Low body weight (less than 127 lbs or 58 kg)",
"      </li>",
"      <li>",
"       Rheumatoid arthritis",
"      </li>",
"      <li>",
"       History of a non-traumatic or low trauma bone fracture in self or parents (eg, breaking a bone after falling from standing height or less)",
"      </li>",
"      <li>",
"       Excessive alcohol consumption (three or more servings a day)",
"      </li>",
"      <li>",
"       A disorder strongly associated with osteoporosis, such as diabetes, untreated hyperthyroidism, hyperparathyroidism, early menopause, chronic malnutrition or malabsorption, or chronic liver disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHICH TEST IS BEST?",
"     </span>",
"    </p>",
"    <p>",
"     There are several different types of bone density tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Dual-energy x-ray absorptiometry (DXA)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Experts agree that the most useful and reliable bone density test is a specialized kind of x-ray called dual-energy x-ray absorptiometry, or DXA. DXA provides precise measurements of bone density at important bone sites (such as the spine, hip, and forearm) with minimal radiation.",
"    </p>",
"    <p>",
"     We recommend DXA of the hip and spine because measurements at these sites are effective for predicting osteoporotic fracture at any site, choosing candidates for therapy, and for monitoring response to therapy. If you are unable to lie on an examination table, it is impossible to measure the spine and hip bone density. Instead, you can sit beside the DXA machine for a scan of your wrist area. When the hip and spine cannot be measured, the diagnosis of osteoporosis can be made using a DXA measurement of the wrist.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Quantitative computerized tomography",
"     </span>",
"     &nbsp;&mdash;&nbsp;This is a type of CT that provides accurate measures of bone density in the spine. Although this test may be an alternative to DXA, it is seldom used because it is expensive and requires a higher radiation dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Ultrasonography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasound can be used to measure the bone density of the heel. This may be useful to determine a person's fracture risk. However, it is used less frequently than DXA because there are no guidelines that use ultrasound measurements to diagnose osteoporosis or predict fracture risk. In areas that do not have access to DXA, ultrasound is an acceptable way to measure bone density.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHAT TO EXPECT FROM A DXA TEST",
"     </span>",
"    </p>",
"    <p>",
"     During DXA, you lie on an examination table. An x-ray detector scans a bone region, and the amount of x-rays that pass through bone are measured and displayed as an image that is interpreted by a radiologist or metabolic bone expert. The test causes no discomfort, involves no injections or special preparation, and usually takes only 5 to 10 minutes. The x-ray detector will detect any metal on your clothing (zippers, belt buckles), so you may be asked to wear a gown for the test.",
"    </p>",
"    <p>",
"     The amount of radiation that's used is minimal, amounting to roughly the same radiation that an average person gets from the environment in one day. After the test is completed and the doctor interprets the results, you will be given a score that speaks to the condition of the bones.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHAT DO THE RESULTS MEAN?",
"     </span>",
"    </p>",
"    <p>",
"     The results of a bone density test are expressed either as a \"T\" or a \"Z\" score. T-scores represent numbers that compare the condition of your bones with those of an average young person with healthy bones. Z scores instead represent numbers that compare the condition of your bones with those of an average person your age. Of these two numbers, the T-score is usually the most important. T-scores are usually in the negative or minus range. The lower the bone density T-score, the greater the risk of fracture (",
"     <a class=\"graphic graphic_table graphicRef74669 \" href=\"UTD.htm?30/26/31147\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Normal bone density",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with normal bone density have a T-score between +1 and -1. People who have a score in this range do not typically need treatment, but it is useful for them to take steps to prevent bone loss, such as having adequate amounts of calcium and vitamin D and doing weight-bearing exercise. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Low bone mass (osteopenia)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Low bone mass (osteopenia) is the term healthcare providers use to describe bone density that is lower than normal but that has not yet reached the low levels seen with osteoporosis.",
"    </p>",
"    <p>",
"     A person with osteopenia does not yet have osteoporosis, but is at risk of developing it. People with osteopenia have a T-score between -1.1 and -2.4.",
"    </p>",
"    <p>",
"     In you have other risk factors for fracture (see",
"     <a class=\"local\" href=\"#H3\">",
"      'Risk factors for fracture'",
"     </a>",
"     above), and have a T-score in the osteopenic range, you may be at high risk for fracture. People with low bone mass are usually advised to take steps to prevent osteoporosis. Sometimes that includes taking medications. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Osteoporosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with osteoporosis have a T-score of -2.5 or less. Larger numbers (eg, -3.2) indicate lower bone density because this is a negative number.",
"    </p>",
"    <p>",
"     The lower the bone density, the greater the risk of fracture. If you discover that you have osteoporosis, there are several things you can do to reduce the chances that you will break a bone. For instance, taking osteoporosis medications combined with calcium and vitamin D supplements and an exercise program can reduce your fracture risk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8101900\">",
"     <span class=\"h2\">",
"      Fracture prediction tool",
"     </span>",
"     &nbsp;&mdash;&nbsp;FRAX is an on-line tool (",
"     <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX\">",
"      file://www.shef.ac.uk/FRAX",
"     </a>",
"     ) that was developed by the World health Organization (WHO) to predict your 10-year likelihood of having a minimal trauma fracture. You can use it to determine your fracture risk even if you have not had a DXA test, but you will get a more accurate prediction if you include DXA results. If you decide to use the FRAX tool on your own, without a DXA study, and the results indicate a high risk of fracture, it is good to also have a DXA test. This DXA will serve as a baseline by which your doctor can follow your response to treatment. Note, too, that to use the FRAX tool, you must know your height in centimeters and your weight in kilograms.",
"    </p>",
"    <p>",
"     The FRAX tool should only be used the first time you",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     your doctor decide that it is time to evaluate your bone health and risk of fracture. It should not be used if you have already had a minimal trauma fracture or are already on treatment aimed at preserving your bone health and preventing future fractures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      DO I NEED TO HAVE BONE DENSITY TESTING AGAIN?",
"     </span>",
"    </p>",
"    <p>",
"     Even if your bone density test shows that you do not have osteoporosis today, you may need to have the test again. How long to wait between tests depends on your initial bone density results and whether you have risk factors that represent an ongoing threat to your bones.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If initial bone density testing shows you have a T-score of -2.00 to -2.49 at any site, or if you take medications that decrease bone density, or have medical conditions that can adversely affect the bones, experts recommend repeat bone density testing every two years.",
"       <br/>",
"       <br/>",
"       Other people may also need repeat bone density testing every two years. This includes people who have osteoporosis and begin taking medications to stall further bone loss or to stimulate new bone growth. The results of the follow-up tests are used to monitor the effects of the treatment.",
"      </li>",
"      <li>",
"       In women 65 years of age and older at baseline screening, with a T-score of -1.50 to -1.99 at any site, and with no risk factors for accelerated bone loss, we will typically perform a follow-up DXA in three to five years.",
"      </li>",
"      <li>",
"       In women 65 years of age and older at baseline screening, with normal or slightly low bone mass (T-score -1.01 to -1.49), and with no risk factors for accelerated bone loss, we will typically perform a follow-up DXA in 10 to 15 years.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Repeat BMD measurements may be most valuable for patients who are taking a medication to treat osteoporosis to determine the efficacy of treatment and for patients who are not being treated but have medical conditions that can cause bone loss to determine if they need treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     Bone density tests help healthcare providers spot bone loss in people who might otherwise have no symptoms. The tests are painless, quick, and safe, and can alert people to bone loss before they have a fracture. The tests are also useful in tracking the effects of medications used to manage bone disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498688658\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063966\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23650?source=see_link\">",
"      Patient information: Bone density testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/45/10962?source=see_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/37/16978?source=see_link\">",
"      Patient information: Cadmium toxicity (Cadmium poisoning) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/41/6803?source=see_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13064038\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"      Prevention of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"      Screening for osteoporosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/007197.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/007197.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Surgeon General",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.surgeongeneral.gov/library/bonehealth/index.html\">",
"      www.surgeongeneral.gov/library/bonehealth/index.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis and Related Bone Diseases National Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Bone/Bone_Health/bone_mass_measure.asp\">",
"      www.niams.nih.gov/Health_Info/Bone/Bone_Health/bone_mass_measure.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Osteoporosis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.nof.org/aboutosteoporosis/detectingosteoporosis/bmdtest\">",
"      www.nof.org/aboutosteoporosis/detectingosteoporosis/bmdtest",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The World Health Organization Fracture Risk Assessment Tool",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"        www.shef.ac.uk/FRAX/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Osteoporosis Society of Canada",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.osteoporosis.ca/\">",
"      www.osteoporosis.ca/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/osteoporosis.cfm\">",
"      www.hormone.org/public/osteoporosis.cfm",
"     </a>",
"     , available in English, Spanish, French, Italian, German, and Portuguese)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/29/1491/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/29/1491?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1491/abstract/1\">",
"      Binkley N, Bilezikian JP, Kendler DL, et al. Summary of the International Society For Clinical Densitometry 2005 Position Development Conference. J Bone Miner Res 2007; 22:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1491/abstract/2\">",
"      Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1491/abstract/3\">",
"      Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164.",
"     </a>",
"    </li>",
"    <li>",
"     National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. file://www.nof.org/professionals/clinical-guidelines (Accessed on April 28, 2008).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_29_1491=[""].join("\n");
var outline_f1_29_1491=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           WHAT DOES BONE DENSITY TESTING DO AND WHY IS IT IMPORTANT?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHO SHOULD GET BONE DENSITY TESTING?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHICH TEST IS BEST?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHAT TO EXPECT FROM A DXA TEST",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHAT DO THE RESULTS MEAN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           DO I NEED TO HAVE BONE DENSITY TESTING AGAIN?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/45/24275\" title=\"figure 1\">",
"           Osteoporosis PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?30/26/31147\" title=\"table 1\">",
"           Bone density definitions PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1492="Mebendazole: Patient drug information";
var content_f1_29_1492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mebendazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=see_link\">",
"     see \"Mebendazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/53/11091?source=see_link\">",
"     see \"Mebendazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vermox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections caused by worms.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702447",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mebendazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet may be crushed and mixed with food or chewed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11786 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-A006EFEBA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1492=[""].join("\n");
var outline_f1_29_1492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191554\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015030\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015029\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015034\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015035\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015037\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015032\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015033\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015038\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015039\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/42/12965?source=related_link\">",
"      Mebendazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/53/11091?source=related_link\">",
"      Mebendazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1493="Second trimester maternal serum screening for Down syndrome";
var content_f1_29_1493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second trimester maternal serum screening for Down syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Jacob A Canick, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Geralyn M Messerlian, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Antonio Farina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1493/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/29/1493/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Down syndrome screening generally involves measurement of various fetoplacental markers in maternal serum to determine the mother's risk of having an affected child. For women who first present for prenatal care after 14 weeks of gestation, the quadruple test is the best screening test using maternal analytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H486544#H486544\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Cell-free free fetal DNA in maternal blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All pregnant women under 20 weeks of gestation should be offered aneuploidy screening [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/1\">",
"     1",
"    </a>",
"    ]. Some women may choose to decline this screening, while others may choose to undergo diagnostic testing instead of screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Candidates for prenatal screening and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIMING AND COLLECTION OF MATERNAL SERUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be encouraged to have their blood sample drawn as early in the screening time frame (15 to 22 weeks of gestation) as possible. Rapid turnaround of results is important to allow time for completion of counseling and follow-up diagnostic testing, if required.",
"   </p>",
"   <p>",
"    A 10 mL sample of blood is drawn and placed into a red top or tiger top collection tube. Under optimal conditions, the sample should be shipped to the laboratory on the day it is obtained. If there is a delay in sending the sample, the serum should be separated from the clot and kept refrigerated until shipped. Analytes are stable in serum for up to one week refrigerated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/2\">",
"     2",
"    </a>",
"    ]; however, laboratories should report screening results within two to three days of sample receipt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     QUADRUPLE TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quadruple test involves measurement of the serum markers alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A in maternal serum, ideally at 15 to 18 weeks of gestation. Maternal serum AFP and uE3 levels are, on average, reduced by 25 to 30 percent in pregnancies affected by Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/3-7\">",
"     3-7",
"    </a>",
"    ], and hCG and inhibin A levels are, on average, twice as high as those in unaffected pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quadruple test is the best available test for Down syndrome screening in women who present for care in the second trimester. It has supplanted the single, double, and triple tests formerly used for this purpose (",
"    <a class=\"graphic graphic_figure graphicRef57445 \" href=\"UTD.htm?19/44/20174\">",
"     figure 1",
"    </a>",
"    ). At a selected midtrimester risk cut-off in the range of 1 in 250 to 1 in 300, the detection rate of the quadruple test is 80 to 83 percent with a false positive rate of 5 percent.",
"   </p>",
"   <p>",
"    A glossary of terms for Down syndrome screening tests is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef76911 \" href=\"UTD.htm?34/33/35355\">",
"     table 1",
"    </a>",
"    ). For comparison, the performance characteristics of a variety of Down syndrome screening tests are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80444 \" href=\"UTD.htm?18/37/19035\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REPORTING RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several software packages are available for Down syndrome screening analysis and reporting. Standard features included in the report are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal date of birth",
"     </li>",
"     <li>",
"      Sample collection date",
"     </li>",
"     <li>",
"      Gestational age at the time of sample collection and method of dating",
"     </li>",
"     <li>",
"      Risk cut-off selected for a screen positive interpretation",
"     </li>",
"     <li>",
"      Risk of Down syndrome based upon maternal age",
"     </li>",
"     <li>",
"      Risk of Down syndrome after screening",
"     </li>",
"     <li>",
"      Clear indication of a screen positive result",
"     </li>",
"     <li>",
"      Recommendation for follow-up in screen positive cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Second trimester serum screening always includes screening for open neural tube defects, using the alpha-fetoprotein component of the test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevated risk of trisomy 18, when present, is also reported. Some screening programs include reporting of elevated risk of Smith-Lemli-Opitz syndrome (SLOS), when present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1406395\">",
"    <span class=\"h1\">",
"     SECONDARY SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend use of ultrasound as a secondary screening tool because it does not have a sufficiently high detection rate for Down syndrome. When the detection rate of a secondary screening test is not close to 100 percent, a proportion of affected pregnancies that were initially identified as screen positive will be incorrectly reclassified as screen negative. Furthermore, a secondary screening delays diagnostic testing.",
"   </p>",
"   <p>",
"    This recommendation is supported by studies that evaluated the role of prenatal ultrasonography in women classified as high risk by either maternal age or serum screening. In 10 studies from 1995 to 2006, over 500 Down syndrome pregnancies and thousands of unaffected pregnancies at high risk of Down syndrome underwent second trimester fetal ultrasound examination for both hard and soft markers of Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/13-22\">",
"     13-22",
"    </a>",
"    ]. The overall detection rate (sensitivity) if one or more markers were visualized was 79 percent (range 50 to 91 percent) and the false positive rate was 12 percent (range 9 to 14 percent). This means that 21 percent of cases originally classified as high risk of Down syndrome would be missed if the negative ultrasound findings were used to guide further management.",
"   </p>",
"   <p>",
"    When secondary ultrasound screening is performed on the general obstetrical population, a completely negative examination lowers the risk of Down syndrome by four- to five-fold. If one or more ultrasound markers of Down syndrome is observed, the risk of Down syndrome increases by six- to seven-fold. Depending on the woman's previously assigned risk (by maternal age or quadruple testing), the ultrasound study can change a screen negative to a screen positive result, or vice versa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H22#H22\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Genetic sonogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, a new test that measures free DNA in plasma is available for secondary screening of high risk women and was endorsed for that purpose in an American College of Obstetricians and Gynecologists (ACOG) committee opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1493/abstract/23\">",
"     23",
"    </a>",
"    ]. The DNA test has very high sensitivity and specificity, leading to a significant reduction in the number of women falsely identified as high risk after serum screening. Some women with a positive serum screen may choose to undergo DNA testing because a negative DNA test may be sufficiently reassuring to allow them to avoid invasive testing for definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient counseling before and after screening is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Basic approach to counseling'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Management of screening results'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"       \"Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The quadruple test for Down syndrome screening is the best screening option for women who present for care after 14 weeks of gestation. It involves measurement of the serum markers alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A in maternal serum, ideally between 15 and 18 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Quadruple test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound examination does not perform well as a secondary screening tool. If used in this way, a proportion of affected pregnancies that were initially identified as screen positive on serum screening will be incorrectly reclassified as screen negative. (See",
"      <a class=\"local\" href=\"#H1406395\">",
"       'Secondary screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/1\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/2\">",
"      Lambert-Messerlian GM, Eklund EE, Malone FD, et al. Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn 2006; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/3\">",
"      Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/4\">",
"      Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984; 1:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/5\">",
"      Wald NJ, Hackshaw AK, George LM. Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. J Med Screen 2000; 7:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/6\">",
"      Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/7\">",
"      Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988; 95:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/8\">",
"      Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987; 7:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/9\">",
"      Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996; 334:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/10\">",
"      Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenat Diagn 2001; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/11\">",
"      Haddow JE, Palomaki GE, Knight GJ, et al. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/12\">",
"      Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/13\">",
"      Bahado-Singh RO, Tan A, Deren O, et al. Risk of Down syndrome and any clinically significant chromosome defect in pregnancies with abnormal triple-screen and normal targeted ultrasonographic results. Am J Obstet Gynecol 1996; 175:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/14\">",
"      Nyberg DA, Luthy DA, Cheng EY, et al. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers. Am J Obstet Gynecol 1995; 173:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/15\">",
"      Egan JF, Malakh L, Turner GW, et al. Role of ultrasound for Down syndrome screening in advanced maternal age. Am J Obstet Gynecol 2001; 185:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/16\">",
"      Bahado-Singh RO, Deren O, Tan A, et al. Ultrasonographically adjusted midtrimester risk of trisomy 21 and significant chromosomal defects in advanced maternal age. Am J Obstet Gynecol 1996; 175:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/17\">",
"      Vintzileos AM, Guzman ER, Smulian JC, et al. Indication-specific accuracy of second-trimester genetic ultrasonography for the detection of trisomy 21. Am J Obstet Gynecol 1999; 181:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/18\">",
"      Vintzileos AM, Guzman ER, Smulian JC, et al. Down syndrome risk estimation after normal genetic sonography. Am J Obstet Gynecol 2002; 187:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/19\">",
"      Wax JR, Guilbert J, Mather J, et al. Efficacy of community-based second trimester genetic ultrasonography in detecting the chromosomally abnormal fetus. J Ultrasound Med 2000; 19:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/20\">",
"      DeVore GR. Trisomy 21: 91% detection rate using second-trimester ultrasound markers. Ultrasound Obstet Gynecol 2000; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/21\">",
"      Hobbins JC, Lezotte DC, Persutte WH, et al. An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies. J Ultrasound Med 2003; 22:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/22\">",
"      Anderson NG, Luehr B, Ng R. Normal obstetric ultrasound reduces the risk of Down syndrome in fetuses of older mothers. Australas Radiol 2006; 50:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1493/abstract/23\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012; 120:1532.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 416 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1493=[""].join("\n");
var outline_f1_29_1493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANDIDATES FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMING AND COLLECTION OF MATERNAL SERUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      QUADRUPLE TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REPORTING RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1406395\">",
"      SECONDARY SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/416|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/44/20174\" title=\"figure 1\">",
"      Down screening test performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/416|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35355\" title=\"table 1\">",
"      Down syndrome screening terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/37/19035\" title=\"table 2\">",
"      Efficiency Down syndrome screen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=related_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1494="Bevacizumab: Patient drug information";
var content_f1_29_1494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bevacizumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     see \"Bevacizumab: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     see \"Bevacizumab: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avastin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3422982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avastin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Holes in the GI (gastrointestinal) tract, wounds not fully healed, fistulas, and very bad bleeding have been reported. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691949",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat macular degeneration.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bevacizumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your urine checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2770240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High or low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A wound that does not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14789071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12346 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1494=[""].join("\n");
var outline_f1_29_1494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141002\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422982\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028935\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028937\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028936\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028941\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028942\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14789071\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028939\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028946\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=related_link\">",
"      Bevacizumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=related_link\">",
"      Bevacizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1495="Juvenile xanthogranuloma (JXG)";
var content_f1_29_1495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Juvenile xanthogranuloma (JXG)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Kate B P&uuml;ttgen, MD, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1495/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/29/1495/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12028554\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile xanthogranuloma (JXG) is a benign, proliferative disorder of histiocytic cells of the dermal dendrocyte phenotype. JXG belongs to the broad group of non-Langerhans cell histiocytoses and is typically a disorder of early childhood. JXG typically presents in the first two years of life as a solitary, reddish or yellowish skin papule or nodule (",
"    <a class=\"graphic graphic_picture graphicRef69122 \" href=\"UTD.htm?28/52/29504\">",
"     picture 1D",
"    </a>",
"    ), most often on the head, neck, or upper trunk. Histologically, JXG is characterized by the presence of histiocytes, foam cells, and Touton giant cells. JXG generally follows a benign course with spontaneous resolution over a period of a few years. Less commonly skin lesions can be multiple (",
"    <a class=\"graphic graphic_picture graphicRef81058 \" href=\"UTD.htm?1/2/1061\">",
"     picture 2B",
"    </a>",
"    ). Extracutaneous or systemic forms are exceedingly rare and can be associated with considerable morbidity.",
"   </p>",
"   <p>",
"    An overview of JXG will be presented here. Langerhans cell histiocytosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028561\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;JXG is the most common of the non-Langerhans cell histiocytoses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence is unknown. In a large tumor registry spanning 35 years, JXG accounted for 129 of 24,600 pediatric tumors (0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2\">",
"     2",
"    </a>",
"    ]. However, this figure may be an underestimate of the relative frequency of JXG since many cases are diagnosed on clinical grounds without histologic confirmation. In a survey of 122 dermatologists with an average of 12 years of practice, 2371 cases of JXG were reported (an average of less than two cases per dermatologist per year); only 7 cases had ocular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JXG may be present at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/4\">",
"     4",
"    </a>",
"    ]. The median ages of onset in two large case series were 5 months (range 0 to 244 months) and 1 year (range 0 to 20 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. The male to female ratio was about 1.4:1.",
"   </p>",
"   <p>",
"    The prognosis of JXG is generally good, with spontaneous resolution of skin and organ lesions over a few years. Rare fatalities have been reported in infants with central nervous system or massive hepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2,5-8\">",
"     2,5-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12028617\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An association between JXG, neurofibromatosis type 1, and juvenile myelomonocytic leukemia (a rare form of childhood leukemia) has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. However, the clinical implications of this triple association are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Juvenile myelomonocytic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028568\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of JXG is unknown. It is a member of the group of histiocytoses, disorders of the mononuclear phagocytic system, which have a broad range of clinical presentations and prognoses.",
"   </p>",
"   <p>",
"    All histiocytoses arise from CD34+ stem cells, which develop, based on the cytokine milieu, into CD14+ or CD14- cells. Langerhans cells (LC) and Langerhans cell histiocytoses (LCH) derive from CD14&ndash; cells. CD14+ cells may become",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    lineage or",
"    <span class=\"nowrap\">",
"     dermal/interstitial",
"    </span>",
"    dendrocytes, the latter considered to be the precursor cell of non-LCH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028575\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404120\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;JXG typically presents as a reddish or yellowish to brown papule, plaque, or nodule (",
"    <a class=\"graphic graphic_picture graphicRef69122 \" href=\"UTD.htm?28/52/29504\">",
"     picture 1D",
"    </a>",
"    ). A size of 0.5 to 2 cm is typical. The lesions can occur in any location, and are most common on the head, neck, and upper trunk. Early lesions tend to be more red and raised, but as they mature and become progressively more lipidized, they appear more yellow and will often flatten. Fine telangiectasias occasionally can be seen overlying the lesion. The lesions usually are solitary (",
"    <a class=\"graphic graphic_picture graphicRef68132 graphicRef81386 graphicRef59377 graphicRef69122 \" href=\"UTD.htm?22/12/22728\">",
"     picture 1A-D",
"    </a>",
"    ), but multiple lesions (",
"    <a class=\"graphic graphic_picture graphicRef68597 graphicRef81058 \" href=\"UTD.htm?18/4/18505\">",
"     picture 2A-B",
"    </a>",
"    ), and extracutaneous and systemic involvement may occur. All organs and systems can be affected.",
"   </p>",
"   <p>",
"    The most common extracutaneous presentation is a solitary nodule or mass in the subcutaneous or deep soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/5\">",
"     5",
"    </a>",
"    ]. Systemic lesions may occur in the liver, lung, spleen, lymph nodes, bones, and the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Eye involvement is rare (0.3 percent of cases identified by dermatologists in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/3\">",
"     3",
"    </a>",
"    ]). It occurs in young children, often without skin involvement. (See",
"    <a class=\"local\" href=\"#H12028582\">",
"     'Ocular JXG'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In two large case series, the distribution of clinical manifestations was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Solitary skin lesion &ndash; 67 and 71 percent",
"     </li>",
"     <li>",
"      Multiple skin lesions &ndash; 7 and 10 percent",
"     </li>",
"     <li>",
"      Superficial or deep soft tissue lesions &ndash; 16 percent and 15 percent",
"     </li>",
"     <li>",
"      Systemic involvement (with or without skin lesions) &ndash; 4 percent and 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most severe cases tend to occur in very young children. In a series of 36 systemic cases the median age was 0.3 years (range 0 to 12 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/6\">",
"     6",
"    </a>",
"    ]. In a study of 45 cases of fetal and neonatal JXG, systemic involvement was observed in 12 patients, 9 of whom had multiple skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/4\">",
"     4",
"    </a>",
"    ]. Liver, lung, spleen, lymph nodes, skeleton, and the gastrointestinal tract were the most common sites involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404113\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous regression is the rule for skin lesions, and occurs in approximately one to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/4\">",
"     4",
"    </a>",
"    ], sometimes leaving an atrophic or hyperpigmented scar. Extracutaneous and systemic JXG also spontaneously regress in most cases.",
"   </p>",
"   <p>",
"    Cases in newborns with multisystem or extensive visceral involvement may require aggressive treatment, but fatalities are exceedingly rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12028610\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028582\">",
"    <span class=\"h2\">",
"     Ocular JXG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular JXG typically occurs in young children. It affects the lid (",
"    <a class=\"graphic graphic_picture graphicRef75895 \" href=\"UTD.htm?8/5/8274\">",
"     picture 3A",
"    </a>",
"    ), orbit, iris (",
"    <a class=\"graphic graphic_picture graphicRef56332 \" href=\"UTD.htm?29/48/30466\">",
"     picture 3B",
"    </a>",
"    ), ciliary body, cornea, and episclera. Ocular JXG may present with spontaneous hyphema (bleeding into the anterior chamber of the eye), uveitis, heterochromia iridis, or iris masses (",
"    <a class=\"graphic graphic_picture graphicRef56332 \" href=\"UTD.htm?29/48/30466\">",
"     picture 3B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Secondary unilateral glaucoma can occur as a result of acute rise in intraocular pressure from mass effect of blood or the JXG itself, and can cause blindness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of glaucoma in infants and children\", section on 'Secondary glaucoma'",
"    </a>",
"    .) Posterior segment involvement is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous findings are absent in approximately one-half of cases of ocular JXG at the time of presentation but may develop before, simultaneous with, or after ocular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028596\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic histology of JXG shows a mixed dermal infiltrate of mononuclear cells, multinucleated giant cells with or without the features of Touton giant cells (characterized by a ring or wreath of nuclei surrounded by a foamy cytoplasm), and spindle cells. Lymphocytes, eosinophils, neutrophils, and mast cells can be seen. The lesion is non-encapsulated but well demarcated, with dense sheets of cells infiltrating the dermis and the upper portion of the subcutaneous fat. Epidermis and adnexae are spared, though the epidermis can be thinned and rarely ulcerated.",
"   </p>",
"   <p>",
"    The microscopic appearance depends upon the age of the lesion. Early JXG shows only histiocytes, or spindle-shaped fibrohistiocytic cells, minimally lipidized. More mature JXG show foamy, lipid-laden vacuolated mononuclear cells and Touton giant cells. Regressing lesions show progressive replacement by fibrous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunostaining is important in establishing the diagnosis. JXG stains positively for Factor XIIIa, a marker of interstitial dendrocytes, CD68, CD163, CD14, and fascin. Stains for S100 and CD1a, which are specific for Langerhans cells, are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028603\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of JXG is made in most cases clinically, based upon clinical appearance; biopsy is infrequently performed because the clinical picture is usually so typical and because of the self-healing nature of the disease. When the diagnosis is in doubt, skin biopsy for histology and immunostaining, is necessary. (See",
"    <a class=\"local\" href=\"#H12028596\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5404435\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical differential diagnosis of JXG in children includes Langerhans cell histiocytosis, other xanthomatous lesions, mastocytoma, Spitz nevus, and dermatofibroma. In most cases the histologic features and immunohistochemistry staining are diagnostic (",
"    <a class=\"graphic graphic_table graphicRef59870 \" href=\"UTD.htm?11/48/12044\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Langerhans cell histiocytosis",
"      </strong>",
"      &ndash; LCH typically presents in infancy as a refractory infantile seborrheic dermatitis with petechiae, diaper dermatitis with ulceration and erosion, cutaneous papules, and nodules (",
"      <a class=\"graphic graphic_picture graphicRef69504 \" href=\"UTD.htm?4/56/4997\">",
"       picture 4",
"      </a>",
"      ). Diabetes insipidus, hepatosplenomegaly, lymphadenopathy, and bone marrow involvement can occur. Individual lesions are typically smaller than those of JXG. On immunostaining of biopsied tissue, LCH is S100 and CD1a positive, but JXG is S100 and CD1a negative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648848#H452648848\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Skin and oral mucosa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Papular xanthoma",
"      </strong>",
"      - Papular xanthoma (",
"      <a class=\"graphic graphic_picture graphicRef72187 \" href=\"UTD.htm?8/36/8769\">",
"       picture 5",
"      </a>",
"      ) is a very uncommon disease that occurs mainly in normolipidemic adults and presents as multiple yellow or red papules or nodules on the trunk and, less frequently, on the head and extremities. Rare pediatric cases have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. The histologic and immunohistochemical differentiation from JXG is difficult. Papular xanthoma presents a dense infiltrate of foam cells, with fewer Touton cells and inflammatory cells than JXG. Immunostaining for factor XIIIa was negative in a series of 10 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberous xanthoma",
"      </strong>",
"      &ndash; Tuberous xanthomas (",
"      <a class=\"graphic graphic_picture graphicRef72875 \" href=\"UTD.htm?32/47/33521\">",
"       picture 6",
"      </a>",
"      ) occur most often in areas of pressure such as the buttocks, knees, and elbows; they are firm, asymptomatic, reddish yellow nodules, seen in patients with hypercholesterolemia and high LDL. Histologically, tuberous xanthoma consists of dermal aggregates of foam cell, with absence of Touton cells or other inflammatory cells.",
"     </li>",
"     <li>",
"      <strong>",
"       Spitz nevus",
"      </strong>",
"      &ndash; Spitz nevi presents as a single, dome shaped, pink to red papule on the face or extremities of children. Histologically, classic Spitz nevi show a symmetrical proliferation of spindle and epithelioid cells, often in nests. Immunostaining confirms the melanocytic origin (S100, Melan-a [Mart-1], and tyrosinase positive) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=see_link&amp;anchor=H25#H25\">",
"       \"Acquired melanocytic nevi (moles)\", section on 'Spitz nevi'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mastocytoma",
"      </strong>",
"      &ndash; Mastocytomas are benign collections of mast cells within the dermis that demonstrate urtication with stroking (Darier sign). They are relatively common in children and appear as reddish to golden brown papules or plaques, which can sometimes have a rubbery feel (",
"      <a class=\"graphic graphic_picture graphicRef80221 graphicRef50284 \" href=\"UTD.htm?25/33/26134\">",
"       picture 7A-B",
"      </a>",
"      ). They are generally asymptomatic but can be mildly pruritic with urtication. Pathology shows mast cells in the papillary dermis highlighted by Giemsa stain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\", section on 'Mastocytomas of the skin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatofibroma",
"      </strong>",
"      &ndash; Dermatofibromas are benign, generally asymptomatic tan to reddish brown papules, seen frequently on the extremities. They often arise after minor inflammation or trauma (eg, folliculitis or insect bite). They are seen more commonly in older children and adults than in infants. Histologically, an acanthotic epidermis with an underlying zone of normal papillary dermis is seen. The lesion is unencapsulated and collagen trapping (spindle cells encasing normal collagen) occurs at the periphery. Spindle cells overlap in fascicles and whorls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link\">",
"       \"Overview of benign lesions of the skin\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101419831#H1101419831\">",
"       \"Overview of benign lesions of the skin\", section on 'Dermatofibroma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of JXG in older children and adults includes xanthoma disseminatum and eruptive xanthoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Xanthoma disseminatum",
"      </strong>",
"      &ndash; Xanthoma disseminatum is a rare form of non-Langerhans cell histiocytosis occurring in young adults, with frequent involvement of mucocutaneous sites. It is often associated with diabetes insipidus. Numerous yellow-brown papules are symmetrically distributed on the trunk and upper extremities. The histologic and immunohistochemical characteristics are the same as JXG.",
"     </li>",
"     <li>",
"      <strong>",
"       Eruptive xanthomas",
"      </strong>",
"      &ndash; Eruptive xanthomas occur in adults in the setting of hypertriglyceridemia, as crops of tiny yellowish red papules on a background of erythema (",
"      <a class=\"graphic graphic_picture graphicRef62471 \" href=\"UTD.htm?7/49/7952\">",
"       picture 8",
"      </a>",
"      ). Sites of predilection include the buttocks, shoulders, and extensor extremities. Facial and oral involvement can occur. Histologically, eruptive xanthoma consists of a dermal infiltrate of histiocytes, lymphocytes, neutrophils, and, in mature lesions, small foam cells. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028610\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of JXG depends upon the site(s) of involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21221319\">",
"    <span class=\"h2\">",
"     Cutaneous JXG",
"    </span>",
"    &nbsp;&mdash;&nbsp;No treatment is needed for cutaneous JXG. Reassurance to patients and parents of affected children about the benign course and spontaneous regression of the disease is usually all that is necessary. Involution usually occurs one to five years after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine referral of all patients with cutaneous JXG for ophthalmologic evaluation is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/3\">",
"     3",
"    </a>",
"    ]. Most patients with ocular involvement present with acute ocular complaints; asymptomatic eye involvement is rare. There are no studies of the benefits of routine ophthalmologic evaluation for children with cutaneous JXG. It is reasonable to consider referral to ophthalmology for patients under age two presenting with multiple JXG, as they may have a higher risk of ocular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21221326\">",
"    <span class=\"h2\">",
"     Subcutaneous and soft tissue JXG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous and soft tissue lesions also resolve spontaneously and do not require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21221333\">",
"    <span class=\"h2\">",
"     Ocular JXG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ocular and periocular lesions should be referred to an ophthalmologist for diagnosis and management. The treatment depends upon the type of ocular involvement and complications.",
"   </p>",
"   <p>",
"    Whether children with cutaneous JXG should be referred for ophthalmologic evaluation is discussed above. (See",
"    <a class=\"local\" href=\"#H21221319\">",
"     'Cutaneous JXG'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21221340\">",
"    <span class=\"h2\">",
"     Symptomatic systemic JXG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lesions that are associated with symptoms (eg, mass effect) may require treatment if they do not spontaneously regress [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/6\">",
"     6",
"    </a>",
"    ]. Treatment decisions for patients with symptomatic systemic JXG should be made on a case-by-case basis. Referral to an oncologist may be warranted. Treatment may involve excision, radiotherapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no standard chemotherapeutic regimen for systemic JXG. A variety of regimens have been tried with variable results (summarized in reference [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/26\">",
"     26",
"    </a>",
"    ]). Most of these regimens included agents that are used in the treatment of LCH (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7975?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/47/15095?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ). Central nervous system involvement has been successfully treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=see_link\">",
"     cladribine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028617\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis of cutaneous JXG is uniformly good; spontaneous regression is the rule. Patients may have residual hyperpigmentation, minimal atrophy, or anetoderma (loss of elastic fibers in the dermis) following regression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extracutaneous JXG most often regresses spontaneously as well, although treatment may be needed to relieve symptoms due to mass effect. Long-term sequelae are rarely reported. Fatalities are extremely rare, typically in infants with central nervous system or massive hepatic involvement and liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1495/abstract/2,5-8,31\">",
"     2,5-8,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12028624\">",
"    <span class=\"h1\">",
"     SUMMARY/RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      JXG is a rare benign, proliferative histiocytic disorder of dermal dendrocyte origin, and is the most common of the non-Langerhans cell histiocytoses. It occurs predominantly in young children. (See",
"      <a class=\"local\" href=\"#H12028561\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical skin lesions appear as reddish to yellow papules, plaques, or nodules, most often on the head and neck, and upper trunk (",
"      <a class=\"graphic graphic_picture graphicRef69122 \" href=\"UTD.htm?28/52/29504\">",
"       picture 1D",
"      </a>",
"      ). Extracutaneous or systemic JXG is rare, occurring in about 4 percent of all cases, and may involve every organ or system, including the eye (",
"      <a class=\"graphic graphic_picture graphicRef75895 graphicRef56332 \" href=\"UTD.htm?29/6/29799\">",
"       picture 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5404120\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular JXG may occur in the absence of skin lesions, and usually presents with ocular manifestations (hyphema, uveitis, iris or corneal lesions) (",
"      <a class=\"graphic graphic_picture graphicRef75895 graphicRef56332 \" href=\"UTD.htm?29/6/29799\">",
"       picture 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12028582\">",
"       'Ocular JXG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is clinical in most cases. In difficult cases, histology and immunohistochemistry are diagnostic. (See",
"      <a class=\"local\" href=\"#H12028603\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of cutaneous JXG includes Langerhans cell histiocytosis (",
"      <a class=\"graphic graphic_picture graphicRef69504 \" href=\"UTD.htm?4/56/4997\">",
"       picture 4",
"      </a>",
"      ); other xanthomatous lesions (such as papular xanthoma, tuberous xanthoma, xanthoma disseminatum, and eruptive xanthoma); Spitz nevus; mastocytoma; and dermatofibroma. (See",
"      <a class=\"local\" href=\"#H5404435\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous JXG generally regresses spontaneously; reassurance about the benign course is usually all that is necessary. Patients with ocular JXG should be referred to an ophthalmologist. Systemic JXG may require treatment (excision, radiotherapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy) if it causes symptoms. (See",
"      <a class=\"local\" href=\"#H12028610\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/1\">",
"      Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/2\">",
"      Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry. Am J Surg Pathol 2005; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/3\">",
"      Chang MW, Frieden IJ, Good W. The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. J Am Acad Dermatol 1996; 34:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/4\">",
"      Isaacs H Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006; 47:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/5\">",
"      Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003; 27:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/6\">",
"      Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996; 129:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/7\">",
"      Azor&iacute;n D, Torrelo A, Lassaletta A, et al. Systemic juvenile xanthogranuloma with fatal outcome. Pediatr Dermatol 2009; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/8\">",
"      Orsey A, Paessler M, Lange BJ, Nichols KE. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/9\">",
"      Raygada M, Arthur DC, Wayne AS, et al. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer 2010; 54:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/10\">",
"      Shin HT, Harris MB, Orlow SJ. Juvenile myelomonocytic leukemia presenting with features of hemophagocytic lymphohistiocytosis in association with neurofibromatosis and juvenile xanthogranulomas. J Pediatr Hematol Oncol 2004; 26:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/11\">",
"      Benessahraoui M, Aubin F, Paratte F, et al. [Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1]. Arch Pediatr 2003; 10:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/12\">",
"      Larr&egrave;gue M, Bela&iuml;ch S, Delzant O, Degos R. [Xanthomatoleukemia in young children and Recklinghausen's disease]. Ann Dermatol Syphiligr (Paris) 1972; 99:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/13\">",
"      Royer, P, Blondet, C, Guihard. Xantholeucemie du nourrisson et neurofibromatose de Recklinghausen. Ann Pediatr (Paris) 1958; 24:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/14\">",
"      Cambiaghi S, Restano L, Caputo R. Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/15\">",
"      Burgdorf WH, Zelger B. JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr Dermatol 2004; 21:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/16\">",
"      Caputo R, Marzano AV, Passoni E, Berti E. Unusual variants of non-Langerhans cell histiocytoses. J Am Acad Dermatol 2007; 57:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/17\">",
"      Vendal Z, Walton D, Chen T. Glaucoma in juvenile xanthogranuloma. Semin Ophthalmol 2006; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/18\">",
"      SANDERS TE. Intraocular juvenile xanthogranuloma (nevoxanthogranuloma): a survey of 20 cases. Trans Am Ophthalmol Soc 1960; 58:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/19\">",
"      Hernandez-Martin A, Baselga E, Drolet BA, Esterly NB. Juvenile xanthogranuloma. J Am Acad Dermatol 1997; 36:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/20\">",
"      Breier F, Zelger B, Reiter H, et al. Papular xanthoma: a clinicopathological study of 10 cases. J Cutan Pathol 2002; 29:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/21\">",
"      Chen CG, Chen CL, Liu HN. Primary papular xanthoma of children: a clinicopathologic, immunohistopathologic and ultrastructural study. Am J Dermatopathol 1997; 19:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/22\">",
"      Fonseca E, Contreras F, Cuevas J. Papular xanthoma in children: report and immunohistochemical study. Pediatr Dermatol 1993; 10:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/23\">",
"      Caputo R, Gianni E, Imondi D, et al. Papular xanthoma in children. J Am Acad Dermatol 1990; 22:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/24\">",
"      Busam KJ, Granter SR, Iversen K, Jungbluth AA. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi. Am J Dermatopathol 2000; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/25\">",
"      Gianotti F, Caputo R. Histiocytic syndromes: a review. J Am Acad Dermatol 1985; 13:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/26\">",
"      Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/27\">",
"      Nakasu S, Tsuji A, Fuse I, Hirai H. Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery. J Neurooncol 2007; 84:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/28\">",
"      De Paula AM, Andr&eacute; N, Fernandez C, et al. Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer 2010; 55:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/29\">",
"      M&uuml;ller RP, Busse H. [Radiotherapy in juvenile xanthogranuloma of the iris]. Klin Monbl Augenheilkd 1986; 189:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/30\">",
"      Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009; 52:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1495/abstract/31\">",
"      Hu WK, Gilliam AC, Wiersma SR, Dahms BB. Fatal congenital systemic juvenile xanthogranuloma with liver failure. Pediatr Dev Pathol 2004; 7:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13729 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.231-4F3FA9F29D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1495=[""].join("\n");
var outline_f1_29_1495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028554\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028561\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028568\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028575\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5404120\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5404113\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12028582\">",
"      Ocular JXG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028596\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028603\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5404435\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028610\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21221319\">",
"      Cutaneous JXG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21221326\">",
"      Subcutaneous and soft tissue JXG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21221333\">",
"      Ocular JXG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21221340\">",
"      Symptomatic systemic JXG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028617\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12028624\">",
"      SUMMARY/RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13729\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13729|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/13/28880\" title=\"picture 1A\">",
"      JXG leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/29/6622\" title=\"picture 1B\">",
"      JXG single face nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/61/13279\" title=\"picture 1C\">",
"      JXG single face nodule 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/52/29504\" title=\"picture 1D\">",
"      JXG solitary lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/60/28612\" title=\"picture 2A\">",
"      JXG multiple scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/2/1061\" title=\"picture 2B\">",
"      JXG multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/5/8274\" title=\"picture 3A\">",
"      Juvenile xanthogranuloma periocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/48/30466\" title=\"picture 3B\">",
"      Intraocular juvenile xanthogranuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/56/4997\" title=\"picture 4\">",
"      Langerhans histiocytosis skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/36/8769\" title=\"picture 5\">",
"      Papular xanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/47/33521\" title=\"picture 6\">",
"      Tuberous xanthoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/12/38095\" title=\"picture 7A\">",
"      Mastocytoma solitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/20/44354\" title=\"picture 7B\">",
"      Mastocytoma extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/49/7952\" title=\"picture 8\">",
"      Eruptive xanthoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13729|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12044\" title=\"table 1\">",
"      Immunohistochemical differential diagnosis of JXG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44056?source=related_link\">",
"      Acquired melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1496="Structure amino acids";
var content_f1_29_1496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Chemical structure of amino acids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 707px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1496=[""].join("\n");
var outline_f1_29_1496=null;
var title_f1_29_1497="Overview of intestinal and multivisceral transplantation";
var content_f1_29_1497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of intestinal and multivisceral transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Farrukh A Khan, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Gennaro Selvaggi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/29/1497/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/29/1497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal transplantation (ITx) has evolved into an established therapeutic modality in the management of the patients with irreversible intestinal failure (IF). It is performed mainly in patients with short bowel syndrome (SBS) and those who develop cholestatic liver disease from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN). Indications for intestinal transplant include depletion of central venous access sites, multiple episodes of catheter related sepsis, electrolyte disturbance, dehydration and progressive cholestatic liver failure.",
"   </p>",
"   <p>",
"    The number of patients who undergo ITx is much lower than for other forms of organ transplantation, and there are fewer",
"    <a class=\"external\" href=\"file://www.cms.gov/CertificationandComplianc/downloads/ApprovedTransplantPrograms.pdf\">",
"     centers",
"    </a>",
"    that perform it. The",
"    <a class=\"external\" href=\"file://optn.transplant.hrsa.gov/latestData/rptData.asp\">",
"     Organ Procurement and Transplantation Network",
"    </a>",
"    reported that in the United States between 1990 and 2010, a total of 2035 ITx were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of ITx was highest in 2007 (198 transplants).",
"   </p>",
"   <p>",
"    This topic review provides an overview of intestinal and multivisceral transplantation. The American Gastroenterological Association (AGA) guideline for short bowel syndrome and intestinal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/2\">",
"     2",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ITx has been performed in children with a variety of causes of SBS including congenital anomalies, necrotizing enterocolitis, intestinal atresia, mid gut volvulus, gastroschisis, and motility disorders (",
"    <a class=\"graphic graphic_figure graphicRef51384 \" href=\"UTD.htm?17/42/18080\">",
"     figure 1",
"    </a>",
"    ). In adults, ITx has been performed mainly in those with SBS related to Crohn's disease, mesenteric thrombosis, trauma, and desmoid tumors (",
"    <a class=\"graphic graphic_figure graphicRef72349 \" href=\"UTD.htm?28/49/29471\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both children and adults, ITx is usually considered in those who developed serious complications related to TPN, such as when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than one-half of the sites typically used for TPN (ie, jugular, subclavian and iliac veins) become inaccessible due to thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catheter related sepsis has resulted in disseminated infections",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      repeated bacteremia.",
"     </li>",
"     <li>",
"      Patients have developed cholestatic liver disease attributable to TPN (such patients may also require liver transplantation). A large database study found that patients with TPN-related liver disease who underwent combined liver and intestinal transplantation had significantly worse outcomes than patients who underwent isolated ITx [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/7\">",
"       7",
"      </a>",
"      ]. The authors suggested that ITx be considered before development of advanced liver disease from TPN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ITx is also performed in patients who do not have short bowel syndrome but have other causes of intestinal failure. These include dysmotility disorders (such as generalized Hirschsprung's disease, megacystis microcolon, intestinal pseudo obstruction), genetic intestinal disorders of the mucosal cells (such as microvillus inclusion disease and tufting enteropathy), disease with a high potential for malignant degeneration (such as familial adenomatous polyposis), neoplastic tumors of the gastrointestinal tract and pancreas that are limited to the abdominal cavity (eg, neuroendocrine tumors), and radiation induced bowel injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Consensus criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Transplantation and the Centers for Medicare and Medicaid Services recommend intestinal transplantation under the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (1) Failure of home parenteral nutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impending or overt liver failure",
"     </li>",
"     <li>",
"      Thrombosis of &ge;2 central veins",
"     </li>",
"     <li>",
"      Two or more episodes per year of systemic sepsis, particularly those requiring hospitalization with shock and fungemia",
"     </li>",
"     <li>",
"      Frequent episodes of dehydration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (2) High risk of death",
"   </p>",
"   <p>",
"    (3) Severe short bowel syndrome (gastrotomy, duodenostomy, residual small bowel &lt;10 cm in infants and &lt;20 cm in adults)",
"   </p>",
"   <p>",
"    (4) Frequent hospitalization, narcotic dependency, or pseudoobstruction",
"   </p>",
"   <p>",
"    (5) Unwillingness to accept long-term home parenteral nutrition",
"   </p>",
"   <p>",
"    The appropriateness of these criteria was confirmed in at least one study that evaluated survival based upon them [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraindications to ITx are similar to liver transplantation. The presence of active infection, aggressive malignancy, multisystem organ failure, cerebral edema, and overt AIDS are absolute contraindications for ITx [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRETRANSPLANT RECIPIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with IF have an extensive medical history and are either home or hospital bound when they are referred for ITx. Transplant evaluation is performed by a multidisciplinary team that includes a transplant clinician,",
"    <span class=\"nowrap\">",
"     hepatologist/gastroenterologist,",
"    </span>",
"    social worker, financial coordinator, nutritionist, and psychologist [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The past medical and surgical histories and prior endoscopic and radiologic evaluations are reviewed in detail (",
"    <a class=\"graphic graphic_table graphicRef59216 \" href=\"UTD.htm?19/14/19693\">",
"     table 1",
"    </a>",
"    ). A liver biopsy is performed in patients with suspected liver disease, although it may be deferred in those with overt clinical features of advanced liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/14\">",
"     14",
"    </a>",
"    ]. Ultrasound of the liver and central veins is obtained to assess the vasculature.",
"   </p>",
"   <p>",
"    Serological studies include testing for cytomegalovirus (CMV), Epstein Barr virus (EBV), human immune deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Blood typing human leukocyte antigen (HLA) is performed for cross matching purpose. Evaluation for hypercoagulability is obtained in patients with history of mesenteric vessel thrombosis.",
"   </p>",
"   <p>",
"    Part of the outcome of the evaluation is to determine whether the patients should undergo ITx alone, or combined ITx and liver or multivisceral transplantation. Combined ITx and liver transplantation may be required in those with IF and end stage liver disease, while a multivisceral transplant may be required in those with IF and the presence of neuropathy or extensive mesenteric thrombosis. Intestinal transplantation without liver transplantation may be feasible in some patients with mild to moderate portal fibrosis and liver dysfunction; improvement in liver histology following intestinal transplantation has been described in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WAIT LIST MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median time to transplant among the patients on the waiting list has decreased over time, from 497 days in 1995 to 142 days in 2008. The waiting time is longer for children and patients with blood group O.",
"   </p>",
"   <p>",
"    Mortality for the patients on the list has improved over time. Mortality is sometimes expressed as deaths per 1000 patient-years at risk (TPYAR). The TPYAR was 130 in 2008 compared with 306 in 2004. In absolute terms, mortality rates have also improved over the last few years, down to 9 percent within one year of listing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DONOR SELECTION/OPERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically stable, donors after brain death who have no intestinal pathology represent the majority of donors. CMV positive donors are accepted for CMV positive recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The donor procurement operation is similar to procurement of the liver. A long midline incision form suprasternal notch to pubic symphysis is made, and the gross anatomy is reviewed with particular attention given to variations in the vascular anatomy of the liver. A biopsy of the liver is performed if there is obvious fatty change.",
"   </p>",
"   <p>",
"    The organs are harvested and generally preserved in University of Wisconsin Solution (UW&reg; solution), although Custodial&reg; solution has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"     18",
"    </a>",
"    ]. Cold Ischemia time is kept to minimum by coordinating timing of the donor operation with the recipient patient's surgery team.",
"   </p>",
"   <p>",
"    The intestinal graft is prepared at the back table. The type of graft is based upon the requirements and condition of the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of anesthesia are similar to those for liver transplantation. However, as noted above, patients with IF often have limited vascular access. As a result, assistance from an interventional radiologist may be required to assure adequate venous access. Transesophageal Doppler ultrasound can also be helpful to monitor cardiac status of the recipient if a Swan-Ganz catheter cannot be positioned or if the patient does not have adequate venous access to allow for it [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General surgical principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recipient operation is started when the donor organs are harvested and deemed satisfactory. The incisions are planned carefully, keeping in mind the presence of the stomas and creation of new stomas. The recipient inflow and outflow vessels are dissected. If an interposition vascular graft is needed it is anastomosed before the new graft is brought to the front table.",
"   </p>",
"   <p>",
"    General surgery principles are followed for restoration of intestinal continuity, with two layer visceral anastomosis. The intestinal anastomosis is constructed in side-to-side fashion to overcome any size discrepancy between the graft and the recipient intestine. A feeding jejunostomy or gastrostomy is created. The distal end of the graft is brought out as a standard end ileostomy or a loop ileostomy. Graft cholecystectomy is performed routinely to reduce the chance of future complications when the liver is included with the graft. Pyloroplasty is performed routinely if the stomach is included in the multivisceral graft. There is an increased trend towards utilization of the donor colon within the allograft since there has been no observed risk of increased postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Isolated intestinal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated intestinal transplantation is performed in patients who have only isolated IF and no associated liver disease (",
"    <a class=\"graphic graphic_figure graphicRef79079 \" href=\"UTD.htm?2/41/2708\">",
"     figure 3",
"    </a>",
"    ). The arterial inflow is usually from the recipient infrarenal aorta and venous outflow to the portal vein (PV). In patients with mesenteric thrombosis, the venous outflow is created to the inferior vena cava (systemic drainage). The PV outflow is preferred due to the concept of hepatotrophic factors providing insulin-like factors for continued optimal hepatocyte function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Liver-intestinal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver-intestinal transplantation (L-ITx) is considered in recipients who have irreversible IF and end-stage liver disease (ESLD) (",
"    <a class=\"graphic graphic_figure graphicRef71185 \" href=\"UTD.htm?33/41/34452\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In small children, the procedure may be modified to include the duodenum and a rim of pancreas to avoid the need for biliary reconstruction. Inclusion of the pancreas (total) has not increased complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some data to suggest that inclusion of the liver helps to confer immunologic tolerance to the small bowel grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the degree of benefit (and shortage of organs) does not appear to justify routine use of such an approach. As a result, a liver transplant is generally reserved for patients who have ESLD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Multivisceral transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multivisceral transplantation (MVTx) includes the stomach, duodenum, pancreas, small intestine, and liver (",
"    <a class=\"graphic graphic_figure graphicRef81359 \" href=\"UTD.htm?16/33/16915\">",
"     figure 5",
"    </a>",
"    ). A modified version excludes the liver, if the recipient liver is normal. A kidney is occasionally included if the recipient has end stage renal disease. Inclusion of the spleen has been proposed as a possible means to reduce the incidence of post-transplant lymphoproliferative disorder, but data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bone marrow infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of donor bone marrow has been proposed as a means to induce immunologic tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/3,18,24\">",
"     3,18,24",
"    </a>",
"    ]. The approaches used include a single infusion within 12 hours of revascularization of the allograft or two to five infusions of donor cells in equally divided doses. However, long-term results have not unequivocally shown advantages in terms of decreasing rejection episodes. As a result, many centers do not use this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Loss of domain/abdominal wall transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal wall closure is quite difficult in some recipients of ITx due to multiple surgical operations, recurrent infections, scar tissue formation, and a contracted abdominal cavity. In difficult cases, the closure is obtained with temporary mesh or Gore-tex grafts. In some cases plastic surgical procedures are required such as rotation flaps to secure the closure of the abdominal wall.",
"   </p>",
"   <p>",
"    Case series have also described abdominal wall transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/25\">",
"     25",
"    </a>",
"    ]. The blood supply is based upon inferior epigastric vessels left in continuity with the donor femoral and iliac vessels. In a series of nine such patients, six patients survived with five intact abdominal walls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/25\">",
"     25",
"    </a>",
"    ]. There were two mild rejection episodes and no episodes of graft versus host disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIVING RELATED TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal transplantation from live donors has been proposed as a means to increase the pool of donor organs and thereby reduce waiting time and wait list morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, living donor transplantation can be performed electively, which may provide an immunologic advantage. Fewer than 40 such procedures have been performed in the last 20 years in the United States, and a similar number have been performed worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During procurement, the donor intestine is measured from the ligament of Treitz to the ileocecal valve. A segment of terminal ileum (200 cm for adult recipients and 150 to 180 cm for pediatric recipients) is harvested 20 cm proximal to the Ileocecal valve. The donor is left with at least 60 percent of the small intestine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Ileal resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest series described 11 recipients who received 12 living related donor ITx [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/27\">",
"     27",
"    </a>",
"    ]. Three-year patient and graft survival were 82 and 75 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal transplantation has been made possible by advances in immunosuppression. The earliest attempts (in the 1960s) failed due to lack of adequate immunosuppressive agents. Success improved dramatically after the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the 1980s and, most notably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in the 1990s.",
"   </p>",
"   <p>",
"    Most centers use an induction regimen that includes anti-lymphocyte (thymoglobulin, ATGAM, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ) or anti-IL-2 receptor antibodies (Simulect), with baseline immunosuppression consisting of a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (TAC), with or without corticosteroids. Initially, TAC is administered intravenously and switched to an oral dose as soon as the intestine resumes normal function. The twelve hour target trough level for TAC is 15 to 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the first 90 days of the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/13,18,30\">",
"     13,18,30",
"    </a>",
"    ]. The new induction protocols have helped to reduce TAC trough levels to 5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after 90 days [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal strategies to use immunosuppressive agents are intensively studied and are evolving. Thus, several immunosuppressant agents and regimens are being used. Other agents commonly utilized are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil, which has helped reduce dose related toxicity of calcineurin agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      , which has the advantage of a low incidence of nephrotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Corticosteroids are used commonly. A bolus is given at the time of transplantation with a taper for five days to a maintenance dose. Corticosteroids are not used as maintenance in patients who receive induction therapy with thymoglobulin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF INTESTINAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal function can be monitored using the d-xylose absorption test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/32\">",
"     32",
"    </a>",
"    ]. Impaired absorption in the early transplant period may be seen with rejection, CMV enteritis, or renal dysfunction. Other tests of intestinal function include fecal fat determination. Intestinal function may be reflected less directly by tolerance to oral feeding, the ability to taper TPN, and serial monitoring of serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;TPN is continued postoperatively until intestinal motility returns to normal, as assessed by bowel sounds and stoma output [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"     18",
"    </a>",
"    ]. Once anastomotic integrity is established, enteral feeds are initiated in the form of an elemental diet through a feeding tube. The enteral feeds are advanced gradually as tolerated.",
"   </p>",
"   <p>",
"    TPN is usually tapered in four to six weeks once the intestine is able to meet full caloric needs of the recipient. Some patients lack appetite. In particular, children who have been on long-term TPN, may need help in learning how to eat again. Most patients continue to need supplemental intravenous fluids and electrolytes due to stoma loss during the first posttransplant year.",
"   </p>",
"   <p>",
"    In a study that included 177 surviving recipients of intestinal and multivisceral transplantations, 160 (90 percent) achieved nutritional autonomy and were able to take an unrestricted oral diet without the need for intravenous nutrition or fluid supplementation after a mean follow-up of 9.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Technical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of technical complications can occur including bleeding, thrombosis and anastomotic leaks. Such complications can lead to serious morbidity and mortality. The rate of such complications has varied across reports, but is probably in the range of 9 percent, although much higher rates have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/34\">",
"     34",
"    </a>",
"    ]. In an illustrative series, 18 of 39 patients (45 percent) required emergency surgery after ITx [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/35\">",
"     35",
"    </a>",
"    ]. Three (8 percent) developed duodenal stump leak resulting in one death, five (13 percent) developed spontaneous small bowel perforation resulting in two deaths, and three (8 percent) needed emergency laparotomy for abdominal compartment syndrome, resulting in two deaths. In another series, technical complications, including intestinal anastomotic leak, hepatic artery thrombosis, and biliary anastomotic leak, led to graft loss in 4 of 35 recipients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/3\">",
"     3",
"    </a>",
"    ]. In other series, the overall incidence of technical complications is described as approximately 9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infectious complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious complications (particularly bacterial infections) are common after ITx and remain the leading cause of death. The most common include intraabdominal or catheter-related sepsis, or sepsis related to bacterial translocation from the graft.",
"   </p>",
"   <p>",
"    Treatment is directed at the underlying cause and may include, in addition to broad spectrum antibiotics, removal of the implicated catheter, treatment against CMV infection, and gut decontamination. Gut decontamination is used when bacterial translocation is suspected, particularly when the patient has acute rejection. Patients are given a mixture of polymyxin, amphotericin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    orally every six hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylaxis against infection is also routinely given, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for Pneumocystis carinii (renamed Pneumocystis jiroveci) infection,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    swish and swallow or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troche four times per day for fungi, and CMV prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Post transplant lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post transplant lymphoproliferative disease develops in up to 30 percent of the recipients of ITx and is usually associated with EBV virus. Treatment principles include a substantial decrease in the immunosuppression regimen and antiviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Graft versus host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) has been reported with all types of organ transplantation. Transplantation of the small bowel was considered to be particularly vulnerable to GVHD since the small intestine contains a large reservoir of lymphocytes, including the Peyer's patches, lamina propria, and large number of mesenteric lymph nodes. Surprisingly, GVHD occurs in only about 7 percent of intestinal transplants, and it tends to be mild in severity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main targets of GVHD are skin, liver, immune system, and gastrointestinal tract. The presentation is usually with a skin rash, mouth or tongue lesions, diarrhea, gastrointestinal ulcerations, liver dysfunction, and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ACUTE REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of rejection (referred to as \"exfoliative\" rejection in reference to the associated loss of intestinal villi) is high in ITx compared with other organs, although there has been some degree of improvement in recent years. The incidence was about 85 percent during the 1990 to 1994 period and 67 percent during the 1995 to 2001 period [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. Mortality associated with severe rejection is about 25 to 45 percent at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/23\">",
"     23",
"    </a>",
"    ]. Graft loss occurs in virtually all patients with severe rejection despite aggressive immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/23,37,38\">",
"     23,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute rejection usually present with increased stoma output, fever, abdominal pain, distension, and ileus. Acute rejection also predisposes to sepsis from bacterial translocation and fungal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made pathologically from specimens obtained during endoscopy. The histologic features of small intestine exfoliative rejection include: a mixed but mostly mononuclear infiltrate with activated lymphocytes, crypt injury, inflammation, and increased crypt cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/39\">",
"     39",
"    </a>",
"    ]. The rejection is graded as indeterminate, mild, moderate, or severe depending upon the extent of the mucosal injury and the degree of inflammatory infiltrate and apoptosis (",
"    <a class=\"graphic graphic_picture graphicRef68676 graphicRef62340 graphicRef74100 \" href=\"UTD.htm?35/40/36490\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ability to diagnose rejection in its earliest stages provides the opportunity to intervene before irreversible complications develop. In the early postoperative period, protocol serial endoscopies through the stoma with intestinal biopsies are commonly used for graft surveillance, since the highest number of rejections is observed within the first month post-transplant. In many centers, serial endoscopy and biopsy are performed twice a week for the first month. After the first month, endoscopies are performed less frequently. After the ileostomy is closed, endoscopies are performed only if indicated by clinical signs or symptoms.",
"   </p>",
"   <p>",
"    Another approach that has been suggested is zoom magnification endoscopy (up to 100-fold magnification), which may reveal suggestive early mucosal changes that may not be visible with standard endoscopy. These include erythema, villous congestion, and blunted and shortened villi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In one series of adults with clinical features suggestive of acute rejection, the sensitivity and specificity of these findings compared with histology were 45 and 98 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar test characteristics were described in children included in the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment typically involves bolus doses of corticosteroids and intensification of the baseline immunosuppressive regimen. Anti T-cell antibodies may be used in steroid-resistant rejection. Unfortunately, more intensive immunosuppression increases the risk of opportunistic infections and the emergence of EBV (which increases the risk of post-transplant lymphoproliferative disorder).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been efforts to reduce rates of rejection by irradiating donor grafts (ex vivo), infusing donor bone marrow, or by leukocyte depletion prior to transplant. In one report, for example, 15 ITx grafts were irradiated ex vivo and recipients also received a single bone marrow infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/43\">",
"     43",
"    </a>",
"    ]. Outcomes were compared with five recipients who served as controls. The incidence of rejection was much lower in the irradiated group (7 versus 80 percent). However, this approach is not used routinely because of the risk of radiation-induced small bowel injury. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bone marrow infusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other approaches have been attempted mainly by modifying the immunosuppressive regimen. In addition, as noted above, the inclusion of a liver may help to protect from rejection of the intestinal graft. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Liver-intestinal transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     CHRONIC REJECTION AND GRAFT FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rejection is observed in about 8 percent of patients undergoing intestinal transplantation. Factors associated with chronic rejection include: isolated ITx compared with small bowel-liver grafts, acute rejection within the first month, increased number and higher grade of acute rejection episodes, older recipient age, non-Caucasian race, and Caucasian to non-Caucasian transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/24,44\">",
"     24,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients usually present with poor intake and lack of appetite, thereby requiring enteral feeding for many months after transplant. The diagnosis can be suggested by intestinal biopsy obtained by endoscopy, or by intestinal function tests (such as d-Xylose absorption). The latter can suggest the diagnosis even before it becomes clinically evident and may be performed as part of a surveillance program [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"     18",
"    </a>",
"    ]. A definitive diagnosis is made with full thickness biopsy of the allograft usually after allograft removal. Characteristic findings include obliteration of submucosal vessels and fibrosis of the allograft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of malabsorption\", section on 'D-xylose test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of ITx with or without transplantation of other organs is in the range of $150,000 to $250,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/45\">",
"     45",
"    </a>",
"    ]. This compares with an estimated annual cost of TPN of $100,000 to $200,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/18\">",
"     18",
"    </a>",
"    ]. ITx is considered to be cost-effective provided that graft function is maintained for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Cost-effectiveness must consider the feasibility of alternatives, the consequences of a failed transplant, and quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data assessing quality of life in recipients of intestinal transplants. In a study of 29 children, quality of life scores were similar to age-matched controls one year after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the assessment of quality of life differed when reported by parents. Parents more frequently reported decreased general health and physical functioning in intestinal transplant recipients. In other studies, quality of life after ITx appeared to be better than or equal to quality of life on TPN [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that included 76 adult recipients of intestinal and multivisceral transplantations, there was improvement in many psychosocial and emotional quality of life domains following transplantation, including anxiety,",
"    <span class=\"nowrap\">",
"     cognitive/emotional",
"    </span>",
"    ability, coping skills, sleep pattern,",
"    <span class=\"nowrap\">",
"     impulsiveness/control,",
"    </span>",
"    social support, and",
"    <span class=\"nowrap\">",
"     leisure/recreation",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/33\">",
"     33",
"    </a>",
"    ]. On the other hand, depression and financial obligations were worse after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Karnofsky scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance status is a measure of a patient's functional capacity. A number of metrics have been developed to quantify performance status; among them, the Karnofsky performance status (KPS) is the most commonly used. The KPS ranges from values of 100, signifying normal functional status with no complaints or evidence of disease, to 0, signifying death (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a summary of 551 recipients, Karnofsky scores of 90 to 100 were observed in 80 percent, 61 to 89 in 10 percent, 31 to 60 in 5 percent, and 1 to 30 in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/28\">",
"     28",
"    </a>",
"    ]. Long-term physical and psychiatric rehabilitation was achieved in 85 percent of ITx recipients who survived beyond six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Graft and patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes in patients undergoing ITx has improved significantly compared with early efforts, with improvements in the immunosuppression protocols and early detection and treatment of rejection. Between 2003 and 2005, there were 252 survivors out of 314 recipients undergoing 323 transplants (ITx 146, liver-ITx 108, and MVTx 69) performed at 29 centers worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/28\">",
"     28",
"    </a>",
"    ]. One-year survival after ITx was approximately 90 percent and 70 percent with liver-ITx. In a later report, one- and five-year patient survival rates were 92 and 70 percent, respectively, in patients who underwent transplantation between 2001 and 2008, suggesting that outcomes continue to improve [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/49\">",
"     49",
"    </a>",
"    ]. However, overall patient survival at 10 and 15 years was only 42 and 35 percent, respectively. Thus, short- and medium-term graft and patient survival have improved, but the long-term results are still disappointing.",
"   </p>",
"   <p>",
"    Various predictors of graft and patient survival have been proposed. In the intestinal transplant registry, graft and patient survival were related to the type of immunosuppression, whereas graft survival was lower with retransplantation and varied across centers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/29/1497/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the most important predictor appeared to be the recipients' status: homebound recipients had a 68 percent survival whereas hospitalized patients had a 42 percent survival at two years. These measures undoubtedly reflected the severity of underlying disease and comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     FUTURE DEVELOPMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The future of ITx appears promising. The surgical technique has been standardized and the immunosuppression regimens are improving. Efforts are focusing on improving immunosuppression protocols including methods to promote tolerance.",
"   </p>",
"   <p>",
"    There will also be improvements in recognition and prevention of complications. The early recognition and treatment of acute rejection to prevent graft loss and associated complications of opportunistic infections and post-transplant lymphoproliferative disease remain a priority. Development of a clinical non-invasive marker for detection of acute rejection in ITx would be helpful.",
"   </p>",
"   <p>",
"    The shortage of appropriate deceased donors contributes to significant wait list mortality, which needs to be overcome, possibly with the increased use of live donors. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Living related transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal transplantation (ITx) has established itself as a therapeutic modality in patients with intestinal failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ITx is performed mainly in patients with short-bowel syndrome who have developed serious complications from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Potential candidates should be referred to transplant centers accredited for ITx. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pretransplant recipient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term outcomes have improved, but remain worse than for other forms of solid-organ transplantation. Three-year recipient survival is approximately 62 percent for ITx and 68 percent for combined liver and intestinal transplantation and for multivisceral transplantation. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Graft and patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quality of life after ITx appears to be better than or equal to quality of life on long-term TPN. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Quality of life'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://optn.transplant.hrsa.gov/latestData/rptData.asp (Accessed on September 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/2\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/3\">",
"      Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg 1995; 222:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/4\">",
"      Reyes JD. Intestinal transplantation. Semin Pediatr Surg 2006; 15:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/5\">",
"      Todo S, Tzakis A, Abu-Elmagd K, et al. Abdominal multivisceral transplantation. Transplantation 1995; 59:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/6\">",
"      Selvaggi G, Gyamfi A, Kato T, et al. Analysis of vascular access in intestinal transplant recipients using the Miami classification from the VIIIth International Small Bowel Transplant Symposium. Transplantation 2005; 79:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/7\">",
"      Chungfat N, Dixler I, Cohran V, et al. Impact of parenteral nutrition-associated liver disease on intestinal transplant waitlist dynamics. J Am Coll Surg 2007; 205:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/8\">",
"      Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/9\">",
"      Kaufman SS, Atkinson JB, Bianchi A, et al. Indications for pediatric intestinal transplantation: a position paper of the American Society of Transplantation. Pediatr Transplant 2001; 5:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/10\">",
"      Pironi L, Forbes A, Joly F, et al. Survival of patients identified as candidates for intestinal transplantation: a 3-year prospective follow-up. Gastroenterology 2008; 135:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/11\">",
"      Abu-Elmagd K, Bond G. Gut failure and abdominal visceral transplantation. Proc Nutr Soc 2003; 62:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/12\">",
"      Abu-Elmagd KM. Intestinal transplantation for short bowel syndrome and gastrointestinal failure: current consensus, rewarding outcomes, and practical guidelines. Gastroenterology 2006; 130:S132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/13\">",
"      Iyer KR, Iverson AK, DeVoll-Zabrocki A, et al. Pediatric intestinal transplantation--review of current practice. Nutr Clin Pract 2002; 17:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/14\">",
"      Bowyer BA, Fleming CR, Ludwig J, et al. Does long-term home parenteral nutrition in adult patients cause chronic liver disease? JPEN J Parenter Enteral Nutr 1985; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/15\">",
"      Fiel MI, Sauter B, Wu HS, et al. Regression of hepatic fibrosis after intestinal transplantation in total parenteral nutrition liver disease. Clin Gastroenterol Hepatol 2008; 6:926.",
"     </a>",
"    </li>",
"    <li>",
"     optn.transplant.hrsa.gov/ar2009 (Accessed on September 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/17\">",
"      Reyes J, Mazariegos GV, Bond GM, et al. Pediatric intestinal transplantation: historical notes, principles and controversies. Pediatr Transplant 2002; 6:193.",
"     </a>",
"    </li>",
"    <li>",
"     Khan FA, Tzakis AG. Intestinal and Multivisceral Transplantation. In: Transplantation, Ginns, Cosmi, Morris (Eds), Blackwell Science, 1999. p.422.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/19\">",
"      Niv Y, Mor E, Tzakis AG. Small bowel transplantation--a clinical review. Am J Gastroenterol 1999; 94:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/20\">",
"      Kato T, Selvaggi G, Gaynor JJ, et al. Inclusion of donor colon and ileocecal valve in intestinal transplantation. Transplantation 2008; 86:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/21\">",
"      Vianna R, Fridell JA, Mangus R, et al. Safe inclusion of the entire pancreas as a component of the multivisceral graft. Transplantation 2008; 86:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/22\">",
"      Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981; 292:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/23\">",
"      Kato T, Tzakis AG, Selvaggi G, et al. Intestinal and multivisceral transplantation in children. Ann Surg 2006; 243:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/24\">",
"      Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg 2001; 234:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/25\">",
"      Levi DM, Tzakis AG, Kato T, et al. Transplantation of the abdominal wall. Lancet 2003; 361:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/26\">",
"      Deltz E, Schroeder P, Gebhardt H, et al. Successful clinical bowel transplantation: report of a case. Clin Transplant 1989; 3:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/27\">",
"      Benedetti E, Holterman M, Asolati M, et al. Living related segmental bowel transplantation: from experimental to standardized procedure. Ann Surg 2006; 244:694.",
"     </a>",
"    </li>",
"    <li>",
"     www.intestinaltransplant.org (Accessed on February 15, 2008).",
"    </li>",
"    <li>",
"     www.optn.org/latestData/rptData.asp (Accessed on February 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/30\">",
"      Mueller AR, Pascher A, Platz KP, et al. Immunosuppression following intestinal transplantation. Transplant Proc 2004; 36:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/31\">",
"      Reyes J, Mazariegos GV, Abu-Elmagd K, et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). Am J Transplant 2005; 5:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/32\">",
"      Kadry Z, Furukawa H, Abu-Elmagd K, et al. Use of the D-xylose absorption test in monitoring intestinal allografts. Transplant Proc 1994; 26:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/33\">",
"      Abu-Elmagd KM, Kosmach-Park B, Costa G, et al. Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg 2012; 256:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/34\">",
"      Flynn B, Park BK, Bond G, et al. Immunosuppressant strategies for intestinal transplantation: a review of a tolerogenic regimen. Prog Transplant 2005; 15:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/35\">",
"      Haghighi KS, Sharif K, Mirza DF, et al. Surgical complications of intestinal transplantation. Transplantation 2006; 82(1 Suppl 2):466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/36\">",
"      Mazariegos GV, Abu-Elmagd K, Jaffe R, et al. Graft versus host disease in intestinal transplantation. Am J Transplant 2004; 4:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/37\">",
"      Wu T, Abu-Elmagd K, Bond G, et al. A schema for histologic grading of small intestine allograft acute rejection. Transplantation 2003; 75:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/38\">",
"      Selvaggi G, Gaynor JJ, Moon J, et al. Analysis of acute cellular rejection episodes in recipients of primary intestinal transplantation: a single center, 11-year experience. Am J Transplant 2007; 7:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/39\">",
"      Tzakis AG, Thompson JF. Current status of diagnosis of small bowel rejection. Pediatr Transplant 1998; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/40\">",
"      Kato T, O'Brien CB, Nishida S, et al. The first case report of the use of a zoom videoendoscope for the evaluation of small bowel graft mucosa in a human after intestinal transplantation. Gastrointest Endosc 1999; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/41\">",
"      Kato T, Gaynor JJ, Nishida S, et al. Zoom endoscopic monitoring of small bowel allograft rejection. Surg Endosc 2006; 20:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/42\">",
"      Lauro A, Altimari A, Di Simone M, et al. Acute cellular rejection monitoring after intestinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. Transplant Proc 2008; 40:1575.",
"     </a>",
"    </li>",
"    <li>",
"     Abu-Elmagd K, Reyes J, Bond G, et al. A novel immunomodulatory strategy for clinical intestinal transplantation: Ex-vivo irradiation with adjunct bone marrow infusion. Program and abstracts of Transplant 2001: The Joint American Transplant Meeting; May 11-16, 2001; Chicago Illinois. Concurrent session 47: Small Bowel Transplantation; Abstract 912.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/44\">",
"      Parizhskaya M, Redondo C, Demetris A, et al. Chronic rejection of small bowel grafts: pediatric and adult study of risk factors and morphologic progression. Pediatr Dev Pathol 2003; 6:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/45\">",
"      Abu-Elmagd KM, Reyes J, Fung JJ, et al. Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Transplant Proc 1999; 31:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/46\">",
"      Sudan D. Cost and quality of life after intestinal transplantation. Gastroenterology 2006; 130:S158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/47\">",
"      Sudan D, Horslen S, Botha J, et al. Quality of life after pediatric intestinal transplantation: the perception of pediatric recipients and their parents. Am J Transplant 2004; 4:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/48\">",
"      O'Keefe SJ, Emerling M, Koritsky D, et al. Nutrition and quality of life following small intestinal transplantation. Am J Gastroenterol 2007; 102:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/29/1497/abstract/49\">",
"      Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg 2009; 250:567.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4595 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-F17749F6BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1497=[""].join("\n");
var outline_f1_29_1497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Consensus criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRETRANSPLANT RECIPIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WAIT LIST MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DONOR SELECTION/OPERATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General surgical principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Isolated intestinal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Liver-intestinal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Multivisceral transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bone marrow infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Loss of domain/abdominal wall transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIVING RELATED TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ASSESSMENT OF INTESTINAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Technical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infectious complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Post transplant lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Graft versus host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ACUTE REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CHRONIC REJECTION AND GRAFT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Karnofsky scores",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Graft and patient survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      FUTURE DEVELOPMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4595|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/42/18080\" title=\"figure 1\">",
"      Intest transplant children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/49/29471\" title=\"figure 2\">",
"      Intest transplant adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/41/2708\" title=\"figure 3\">",
"      Isolated intest transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/41/34452\" title=\"figure 4\">",
"      Liver and small bowel transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/33/16915\" title=\"figure 5\">",
"      Multivisceral transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4595|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/36/28228\" title=\"picture 1A\">",
"      Mild acute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/6/9319\" title=\"picture 1B\">",
"      Severe acute rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/8/30852\" title=\"picture 1C\">",
"      Severe rejection graft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/14/19693\" title=\"table 1\">",
"      Multivisceral transplant evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1498="Vincristine (conventional): Drug information";
var content_f1_29_1498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vincristine (conventional): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/7/42100?source=see_link\">",
"    see \"Vincristine (conventional): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"    see \"Vincristine (conventional): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vincasar PFS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10518612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vincristine Sulfate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Vinca Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses may be capped at a maximum of 2 mg/dose. Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Doses in the manufacturer&rsquo;s U.S. labeling: I.V.: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; frequency may vary based on protocol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional dosing in combination therapy; indication-specific and/or unlabeled dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic leukemia (ALL):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hyper-CVAD regimen: 2 mg/dose days 4 and 11 during odd-numbered cycles (cycles 1, 3, 5, 7) of an 8-cycle phase, followed by maintenance treatment (if needed) of 2 mg monthly for 2 years (Kantarjian, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Larson (CALBG 8811) regimen: Induction phase: 2 mg/dose days 1, 8, 15, and 22 (4-week treatment cycle); Early intensification phase: 2 mg/dose days 15, and 22 (4-week treatment cycle, repeat once); Late intensification phase: 2 mg/dose days 1, 8, 15 (8-week treatment cycle); Maintenance phase: 2 mg/dose day 1 every 4 weeks until 24 months from diagnosis (Larson, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Central nervous system tumors:",
"     </b>",
"     I.V.: PCV regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on days 8 and 29 of a 6-week treatment cycle for a total of 6 cycles (van de Bent, 2006)",
"     <b>",
"      or",
"     </b>",
"     1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (no maximum dose) on days 8 and 29 of a 6-week treatment cycle for up to 4 cycles (Cairncross, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     BEACOPP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 8 of a 21-day treatment cycle (Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Stanford-V regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) in weeks 2, 4, 6, 8, 10, and 12 (Horning, 2000; Horning, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Burkitt lymphoma:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     CODOX-M/IVAC: Cycles 1 and 3 (CODOX-M): 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (no maximum dose) days 1 and 8 of cycle 1 and days 1, 8, and 15 of cycle 3 (Magrath, 1996)",
"     <b>",
"      or",
"     </b>",
"     1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) days 1 and 8 of cycles 1 and 3 (Mead 2002; Mead 2008); CODOX-M is in combination with cyclophosphamide, doxorubicin, methotrexate, and CNS prophylaxis and alternates with IVAC (etoposide, ifosfamide, mesna, cytarabine, and CNS prophylaxis) for a total of 4 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hyper-CVAD: 2 mg (flat dose) days 4 and 11 of courses 1, 3, 5, and 7 (in combination with cyclophosphamide, doxorubicin, and dexamethasone) and alternates with even courses 2, 4, 6, and 8 (methotrexate and cytarabine) (Thomas, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Follicular lymphoma:",
"     </i>",
"     CVP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with cyclophosphamide and prednisone) for 8 cycles (Marcus, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Large B-cell lymphoma:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     CHOP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 8 cycles (Coiffier, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     EPOCH regimen: 0.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle; dose not usually capped) of a 21-day treatment cycle (Wilson, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma (unlabeled use):",
"     </b>",
"     I.V.: VAC/IE regimen: VAC: 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle (in combination with doxorubicin and cyclophosphamide), alternates with IE (ifosfamide and etoposide) for a total of 17 cycles (Grier, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Gestational trophoblastic tumors, high-risk (unlabeled use):",
"     </b>",
"     I.V.: EMA/CO regimen: 1 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of 2-week treatment cycle (in combination with etoposide methotrexate, dactinomycin, and cyclophosphamide), continue for at least 2 treatment cycles after a normal hCG level (Escobar, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     DVD regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 28-day treatment cycle (Rifkin, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     VAD regimen: 0.4 mg/day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/cycle) of a 28-day treatment cycle (Rifkin, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer (unlabeled use):",
"     </b>",
"     I.V.: VAC regimen: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weekly for 8-12 weeks (Slayton, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer (unlabeled use):",
"     </b>",
"     I.V.: CAV regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose day 1 of a 21-day treatment cycle (Hong, 1989)",
"     <b>",
"      or",
"     </b>",
"     2 mg/dose on day 1 of a 21-day treatment cycle (von Pawel, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Thymoma, advanced (unlabeled use):",
"     </b>",
"     I.V.: ADOC regimen: 0.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 3 every 3 weeks (in combination with cisplatin, doxorubicin, and cyclophosphamide) (Fornasiero, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in obesity:",
"     </b>",
"     Dose should be capped at a maximum of 2 mg due to neurotoxicity concerns (Griggs, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"      see \"Vincristine (conventional): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses may be capped at a maximum of 2 mg/dose. Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Doses in the manufacturer&rsquo;s U.S. labeling: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &le;10 kg: 0.05 mg/kg/dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &gt;10 kg: 1.5-2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; frequency may vary based on protocol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Additional dosing in combination therapy; indication-specific and/or unlabeled dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acute lymphocytic lymphoma (ALL):",
"     </b>",
"     I.V.: Induction phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 7, 14, and 21; Consolidation phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 28, and 56; Delayed intensification phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 7, and 14; Maintenance phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 28, and 56 (Bostrom, 2003)",
"     <b>",
"      or",
"     </b>",
"     Induction phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 7, 14, and 21; Consolidation phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 28, and 56; Interim maintenance phases: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0 and 28; Delayed intensification phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 0, 7, and 14; Maintenance phase: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 4 weeks (Avramis, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Burkitt lymphoma and B-cell ALL:",
"     </b>",
"     I.V.: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) on days 4 and 11 of initial phase cycle (initial phase is in combination with cyclophosphamide, doxorubicin, and CNS prophylaxis; alternates with secondary phase) for a total of 4 cycles of each phase (Bowman, 1996)",
"     <b>",
"      or",
"     </b>",
"     1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) on day 1 of cycle AA (in combination with dexamethasone, ifosfamide, methotrexate, cytarabine, etoposide and CNS prophylaxis) and on day 1 of cycle BB (in combination with dexamethasone, cyclophosphamide, methotrexate, doxorubicin, and CNS prophylaxis) (Reiter, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ewing's sarcoma (unlabeled use):",
"     </b>",
"     I.V.: 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 21-day cycle, administer either every cycle or during odd-numbered cycles (Grier, 2003)",
"     <b>",
"      or",
"     </b>",
"     0.67 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1, 2, and 3 (total 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle; maximum dose/cycle: 2 mg) during cycles 1, 2, 3, and 6 (Kolb, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma:",
"     </b>",
"     I.V.: BEACOPP regimen: 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 7 of a 21-day treatment cycle (Kelly, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     CE-CAdO regimen: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) days 1 and 5 every 21 days for 2 cycles (Rubie, 1998)",
"     <b>",
"      or",
"     </b>",
"     0.05 mg/kg days 1 and 5 for 2 cycles (Rubie, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     CAV-P/VP regimen (unlabeled dosing): 0.033 mg/kg/day continuous infusion days 1, 2, and 3, then 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus day 9 of courses 1, 2, 4, and 6 (Kushner, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Retinoblastoma (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children: 0.05 mg/kg on day 1 every 21 days (in combination with carboplatin) for 8 cycles (Rodriguez-Galindo, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &le;36 months: 0.05 mg/kg on day 0 every 28 days (in combination with carboplatin and etoposide) for 6 cycles (Freidman, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;36 months: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) on day 0 every 28 days (in combination with carboplatin and etoposide) for 6 cycles (Friedman, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Rhabdomyosarcoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     VA regimen: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 1-8, weeks 13-20, and weeks 25-32 (Crist, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     VAC regimen: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 0-12, week 16, weeks 20-25; Continuation therapy: Weeks 29-34, and weeks 38-43 (Crist, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Wilms' tumor:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &lt;1 year: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 10-11 weeks, then every 3 weeks for 15 additional weeks (total 25-26 weeks) (Pritchard, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;1 year: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 10-11 weeks, then every 3 weeks for 15 additional weeks (total 25-26 weeks) (Pritchard, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &le;30 kg: 0.05 mg/kg/dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 0.067 mg/kg/dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24 (Green, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;30 kg: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24 (Green, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5528839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary (Kintzel, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The manufacturer&rsquo;s labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Floyd, 2006: Serum bilirubin 1.5-3 mg/dL or transaminases 2-3 times ULN or alkaline phosphatase increased: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Superfin, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serum bilirubin 1.5-3 mg/dL: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Serum bilirubin &gt;3 mg/dL: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 1 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vincasar PFS&reg;: 1 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For I.V. administration only.  FATAL IF GIVEN INTRATHECALLY.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Usually administered as short 5-10 minute infusion (preferred); may also be administered as a slow (1 minute) push or by a 24-hour continuous infusion (depending on the protocol).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do",
"     <b>",
"      NOT",
"     </b>",
"     flush the line); initiate hyaluronidase antidote; apply dry warm compresses for 20 minutes 4 times a day for 1-2 days; elevate extremity. Hyaluronidase: If needle/cannula still in place, administer 1-6 mL hyaluronidase (150 units/mL) into the existing I.V. line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo, 2012; Schulmeister, 2011). If needle/cannula has been removed, inject 1-6 mL (150 units/mL) subcutaneously in a clock wise manner using 1 mL for 1 mL of drug extravasated (Schulmeister, 2011)",
"     <b>",
"      or",
"     </b>",
"     administer 1 mL  (150 units/mL) as 5 separate 0.2 mL injections (25-gauge needle) subcutaneously into the extravasation site (Polovich, 2009). Remaining portion of the vincristine dose should be infused through a separate vein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bleomycin, caspofungin, cisplatin, cladribine, cyclophosphamide, doxorubicin HCl, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, gemcitabine, granisetron, heparin, leucovorin calcium, linezolid, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, topotecan, vinblastine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, furosemide, idarubicin, sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxapram, doxorubicin, droperidol, fluorouracil, heparin, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9349176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of central nervous system tumors, chronic lymphocytic leukemia (CLL), Ewing&rsquo;s sarcoma, gestational trophoblastic tumors (high-risk), multiple myeloma, ovarian germ cell tumors, retinoblastoma, small cell lung cancer (SCLC); thymoma (advanced)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VinCRIStine may be confused with vinBLAStine, vinorelbine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VinCRIStine conventional may be confused with vinCRIStine liposomal",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oncovin may be confused with Ancobon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For I.V. use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is recommended that vincristine doses be dispensed in a small minibag. Vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location",
"       <b>",
"        away",
"       </b>",
"       from the separate storage location recommended for intrathecal medications. Vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hyper-/hypotension, MI, myocardial ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, coma, cranial nerve dysfunction (auditory damage, extraocular muscle impairment, laryngeal muscle impairment, paralysis, paresis, vestibular damage, vocal cord paralysis), dizziness, fever, headache, neurotoxicity (dose-related), neuropathic pain (common), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic toxicity: Alopecia (common), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia, parotid pain, SIADH (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation (common), diarrhea, intestinal necrosis, intestinal perforation, nausea, oral ulcers, paralytic ileus, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder atony, dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (mild), leukopenia (mild), thrombocytopenia (mild), thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis, tissue irritation/necrosis (if infiltrated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, bone pain, deep tendon reflex loss, difficulty walking, foot drop, gait changes, jaw pain, limb pain, motor difficulties, muscle wasting, myalgia, paralysis, paresthesia, peripheral neuropathy (common), sensorimotor dysfunction, sensory loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cortical blindness (transient), nystagmus, optic atrophy with blindness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute uric acid nephropathy, hemolytic uremic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pharyngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (rare), anaphylaxis (rare), hypersensitivity (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with the demyelinating form of Charcot-Marie-Tooth syndrome",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, paralytic ileus, intestinal necrosis and/or perforation  may occur; constipation may present as upper colon impaction with an empty rectum (may require flat film of abdomen for diagnosis); generally responds to high enemas and laxatives. All patients should be on a prophylactic bowel management regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Alterations in mental status such as depression, confusion, or insomnia may occur; neurologic effects are dose-limiting (may require dosage reduction) and may be additive with those of other neurotoxic agents and spinal cord irradiation. Use with caution in patients with pre-existing neuromuscular disease and/or with concomitant neurotoxic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory effects: Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin. Onset may be several minutes to hours after vincristine administration and up to 2 weeks after mitomycin. Progressive dyspnea may occur. Permanently discontinue vincristine if pulmonary dysfunction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uric acid nephropathy: Acute uric acid nephropathy has been reported with vincristine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage modification required. May be associated with hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), increased risk in children &lt;3 years of age; use with caution in hepatobiliary dysfunction. Monitor for signs or symptoms of hepatic SOS, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; avoid eye contamination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Not for intrathecal administration:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. administration only; inadvertent intrathecal administration usually results in death.",
"     </b>",
"     To prevent administration errors, the World Health Organization recommends dispensing vincristine diluted in a minibag (WHO, 2007),",
"     <b>",
"      if not dispensed in a minibag, affix an auxiliary label stating &ldquo;For intravenous use only - fatal if given by other routes&rdquo; and also place in an overwrap labeled &ldquo;Do not remove covering until moment of injection.&rdquo;",
"     </b>",
"     Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location",
"     <b>",
"      away",
"     </b>",
"     from the separate storage location recommended for intrathecal medications. Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vesicant:",
"     <b>",
"      [U.S. Boxed Warning]: Vincristine is a vesicant; avoid extravasation. Ensure proper catheter or needle position prior to (and during) infusion, individuals administering should be experienced in vincristine administration. Discontinue administration immediately if extravasation occurs and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: May increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: May enhance the neurotoxic effect of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease vincristine levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10517724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10517725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue vincristine or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vincasar PFS Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $18.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (VinCRIStine Sulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $6.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes (sodium), hepatic function tests, CBC with differential, serum uric acid; monitor infusion site; neurologic examination, monitor for constipation/ileus and for signs/symptoms of peripheral neuropathy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alcavixin (PH);",
"     </li>",
"     <li>",
"      Biocristin (IN);",
"     </li>",
"     <li>",
"      Citomid RU (MX, TH);",
"     </li>",
"     <li>",
"      Cristovin (IL);",
"     </li>",
"     <li>",
"      Cytocristin (BG, IN);",
"     </li>",
"     <li>",
"      Dabaz (BR);",
"     </li>",
"     <li>",
"      Farmistin CS (DE);",
"     </li>",
"     <li>",
"      Kyocristine (JP);",
"     </li>",
"     <li>",
"      Oncocristin (CO, PE);",
"     </li>",
"     <li>",
"      Oncovin (AT, AU, BF, BJ, BR, CH, CI, CN, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HN, HR, IE, IT, KE, LR, LU, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, PK, PL, PT, RU, SC, SD, SE, SK, SL, SN, TN, TR, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Vinces (AR);",
"     </li>",
"     <li>",
"      Vincran (KP);",
"     </li>",
"     <li>",
"      Vincrina (PY);",
"     </li>",
"     <li>",
"      Vincrisin (BE);",
"     </li>",
"     <li>",
"      Vincristin (HU, PL);",
"     </li>",
"     <li>",
"      Vincristina (IT);",
"     </li>",
"     <li>",
"      Vincristine Delta West (HR);",
"     </li>",
"     <li>",
"      Vincristine Sulfate (PL);",
"     </li>",
"     <li>",
"      Vincristine-David Bull (LU);",
"     </li>",
"     <li>",
"      Vincrisul (ES);",
"     </li>",
"     <li>",
"      Vinracine (HK, MY, SG);",
"     </li>",
"     <li>",
"      Vintec (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vincristine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Rapidly removed from bloodstream and tightly bound to tissues; penetrates blood-brain barrier poorly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 85 hours (range: 19-155 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~80%); urine (10% to 20%; &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arndt C, Hawkins, D, Anderson JR, et al, &ldquo;Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(10):1894-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/15143082/pubmed\" id=\"15143082\" target=\"_blank\">",
"        15143082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 102, 174.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avramis VI, Sencer S, Periclou AP, et al, &ldquo;A Randomized Comparison of Native",
"      <i>",
"       Escherichia coli",
"      </i>",
"      Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(6):1986-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11877270/pubmed\" id=\"11877270\" target=\"_blank\">",
"        11877270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barlogie B, Smith L, and Alexanian R, &ldquo;Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(21):1353-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/6546971 /pubmed\" id=\"6546971 \" target=\"_blank\">",
"        6546971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bermudez M, Fuster JL, Llinares E, et al, &ldquo;Itraconazole-Related Increased Vincristine Neurotoxicity: Case Report and Review of Literature,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2005, 27(7):389-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16012330/pubmed\" id=\"16012330\" target=\"_blank\">",
"        16012330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berruti A, Borasio P, Gerbino A, et al, &ldquo;Primary Chemotherapy With Adriamycin, Cisplatin, Vincristine and Cyclophosphamide in Locally Advanced Thymomas: A Single Institution Experience,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1999, 81(5):841-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/10555755/pubmed\" id=\"10555755\" target=\"_blank\">",
"        10555755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bohme A, Ganser A, and Hoelzer D, &ldquo;Aggravation of Vincristine-Induced Neurotoxicity by Itraconazole in the Treatment of Adult ALL,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 1995, 71(6):311-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/8534764/pubmed\" id=\"8534764\" target=\"_blank\">",
"        8534764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bostrom BC, Sensel MR, Sather HN, et al, &ldquo;Dexamethasone Versus Prednisone and Daily Oral Versus Weekly Intravenous Mercaptopurine for Patients With Standard-Risk Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 101(10):3809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12531809/pubmed\" id=\"12531809\" target=\"_blank\">",
"        12531809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bowman WP, Shuster JJ, Cook B, et al, &ldquo;Improved Survival for Children With B-Cell Acute Lymphoblastic Leukemia and Stage IV Small Noncleaved-Cell Lymphoma: A Pediatric Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(4):1252-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/8648381/pubmed\" id=\"8648381\" target=\"_blank\">",
"        8648381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairncross G, Berkey B, Shaw E, et al, &ldquo;Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2707-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16782910/pubmed\" id=\"16782910\" target=\"_blank\">",
"        16782910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coiffier B, Lepage E, Briere J, et al, &ldquo;CHOP Chemotherapy Plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse Large-B-Cell Lymphoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(4):235-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11807147/pubmed\" id=\"11807147\" target=\"_blank\">",
"        11807147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crist WM, Anderson JR, Meza JL, et al, &ldquo;Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(12):3091-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11408506/pubmed\" id=\"11408506\" target=\"_blank\">",
"        11408506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, &ldquo;Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donelli MG, Zucchetti M, Munzone E, et al,  &ldquo;Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1998, 34(1):33-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/9624235/pubmed\" id=\"9624235\" target=\"_blank\">",
"        9624235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eiden C, Palenzuela G, Hillaire-Buys D, et al, &ldquo;Posaconazole-Increased Vincristine Neurotoxicity in a Child: A Case Report,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2009, 31(4):292-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/19346885/pubmed\" id=\"19346885\" target=\"_blank\">",
"        19346885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escobar PF, Lurain JR, Singh DK, et al, &ldquo;Treatment of High-Risk Gestational Trophoblastic Neoplasia With Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine Chemotherapy,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2003, 91(3):552-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/14675675/pubmed\" id=\"14675675\" target=\"_blank\">",
"        14675675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fornasiero A, Daniele O, Ghiotto C, et al, &ldquo;Chemotherapy for Invasive thymoma. A 13-year Experience,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1991, 68(1):30-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/2049749/pubmed\" id=\"2049749\" target=\"_blank\">",
"        2049749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman DL, Himelstein B, Shields CL, et al, \"Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(1):12-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/10623688/pubmed\" id=\"10623688\" target=\"_blank\">",
"        10623688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green DM, Breslow NE, Beckwith JB, et al, &ldquo;Effect of Duration of Treatment on Treatment Outcome and Cost of Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(12):3744-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/9850017 /pubmed\" id=\"9850017 \" target=\"_blank\">",
"        9850017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green DM, Cotton CA, Malogolowkin M, et al, &ldquo;Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2007, 48(5):493-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16547940/pubmed\" id=\"16547940\" target=\"_blank\">",
"        16547940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, &ldquo;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hong WK, Nicaise C, Larson R, et al, &ldquo;Etoposide Combined With Cyclophosphamide Plus Vincristine Compared With Doxorubicin Plus Cyclophosphamide Plus Vincristine and With High-Dose Cyclophosphamide Plus Vincristine in the Treatment of Small-Cell Carcinoma of the Lung: A Randomized Trial of the Bristol Lung Cancer Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1989, 7(4):450-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/2538577/pubmed\" id=\"2538577\" target=\"_blank\">",
"        2538577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Hoppe RT, Breslin S, et al, &ldquo;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11821442/pubmed\" id=\"11821442\" target=\"_blank\">",
"        11821442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Williams J, Bartlett NL, et al, &ldquo;Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(5):972-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/10694546/pubmed\" id=\"10694546\" target=\"_blank\">",
"        10694546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Thomas D, O'Brien S, et al, &ldquo;Long-Term Follow-Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD), A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(12):2788-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/15481055/pubmed\" id=\"15481055\" target=\"_blank\">",
"        15481055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, Hutchinson RJ, Sposto R, et al, \"Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(Suppl 1):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12078889/pubmed\" id=\"12078889\" target=\"_blank\">",
"        12078889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kolb EA, Kushner BH, Gorlick R, et al, &ldquo;Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(18):3423-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12972518/pubmed\" id=\"12972518\" target=\"_blank\">",
"        12972518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2607-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/7527454 /pubmed\" id=\"7527454 \" target=\"_blank\">",
"        7527454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/7718875/pubmed\" id=\"7718875\" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, &ldquo;Vincristine Neurotoxicity. Pathophysiology and Management,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(6):421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/3540519/pubmed\" id=\"3540519\" target=\"_blank\">",
"        3540519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magrath I, Adde M, Shad A, et al, &ldquo;Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(3):925-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/8622041 /pubmed\" id=\"8622041 \" target=\"_blank\">",
"        8622041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcus R, Imrie K, Belch A, et al, &ldquo;CVP Chemotherapy Plus Rituximab Compared With CVP as First-Line Treatment for Advanced Follicular Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 105(4):1417-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/15494430/pubmed\" id=\"15494430\" target=\"_blank\">",
"        15494430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCune JS and Lindley C, &ldquo;Appropriateness of Maximum-Dose Guidelines for Vincristine,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(15):1755-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/9262750/pubmed\" id=\"9262750\" target=\"_blank\">",
"        9262750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Barrans SL, Qian W, et al, \"A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(6):2248-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/18612102/pubmed\" id=\"18612102\" target=\"_blank\">",
"        18612102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Sydes MR, Walewski J, et al, \"An International Evaluation of CODOX-M and CODOX-M Alternating With IVAC in Adult Burkitt's Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(8):1264-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12181251/pubmed\" id=\"12181251\" target=\"_blank\">",
"        12181251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polovich M, Whitford JN and Olsen M,",
"      <i>",
"       Chemotherapy and Biotherapy Guidelines and Recommendations for Practice",
"      </i>",
"      , 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritchard J, Imeson J, Barnes J, et al, &ldquo;Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(1):124-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/799012/pubmed\" id=\"799012\" target=\"_blank\">",
"        799012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiter A, Schrappe M, Tiemann M, et al, &ldquo;Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1999, 94(10):3294-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/10552938/pubmed\" id=\"10552938\" target=\"_blank\">",
"        10552938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rifkin RM, Gregory SA, Mohrbacher A, et al, &ldquo;Pegylated Liposomal Doxorubicin, Vincristine, and Dexamethasone Provide Significant Reduction in Toxicity Compared With Doxorubicin, Vincristine, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: A Phase III Multicenter Randomized Trial,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(4):848-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16404741/pubmed\" id=\"16404741\" target=\"_blank\">",
"        16404741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Wilson MW, Haik BG, et al, \"Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(10):2019-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12743157/pubmed\" id=\"12743157\" target=\"_blank\">",
"        12743157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1998, 77(12):2310-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/9649151 /pubmed\" id=\"9649151 \" target=\"_blank\">",
"        9649151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Plantaz D, Coze C, et al, \"Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,\"",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 2001, 36(1):247-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11464897/pubmed\" id=\"11464897\" target=\"_blank\">",
"        11464897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulmeister L, \"Extravasation Management: Clinical Update,\"",
"      <i>",
"       Semin Oncol Nurs",
"      </i>",
"      , 2011, 27(1):82-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/21255716/pubmed\" id=\"21255716\" target=\"_blank\">",
"        21255716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shields CL, Honavar SG, Meadows AT, et al, \"Chemoreduction for Unilateral Retinoblastoma,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2002, 120(12):1653-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12470138/pubmed\" id=\"12470138\" target=\"_blank\">",
"        12470138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slayton RE, Park RC, Silverberg SG, et al, &ldquo;Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report),&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1985, 56(2):243-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/2988740/pubmed\" id=\"2988740\" target=\"_blank\">",
"        2988740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stefanou A and Dooley M, &ldquo;Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 21(10):2044.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12743160/pubmed\" id=\"12743160\" target=\"_blank\">",
"        12743160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Superfin D, Iannucci AA, and Davies AM, &ldquo;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2007, 12(9):1070-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/17914077/pubmed\" id=\"17914077\" target=\"_blank\">",
"        17914077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sussman DA, Escalona-Benz E, Benz MS, et al, \"Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2003, 121(7):979-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/12860801/pubmed\" id=\"12860801\" target=\"_blank\">",
"        12860801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas DA, Faderi S, O&rsquo;Brien S, et al, &ldquo;Chemoimmunotherapy With Hyper-CVAD Plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(7):1569-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16502413/pubmed\" id=\"16502413\" target=\"_blank\">",
"        16502413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bent MJ, Carpentier AF, Brandes AA, et al, &ldquo;Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival But Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2715-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/16782911 /pubmed\" id=\"16782911 \" target=\"_blank\">",
"        16782911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Pawel J, Schiller JH, Shepherd FA, et al, &ldquo;Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(2):658-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/10080612/pubmed\" id=\"10080612\" target=\"_blank\">",
"        10080612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson WH, Grossbard ML, Pittaluga S, et al, &ldquo;Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach With High Efficacy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):2685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/29/1498/abstract-text/11929754/pubmed\" id=\"11929754\" target=\"_blank\">",
"        11929754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Vincristine (and Other Vinca Alkaloids) Should Only Be Given Intravenously via a Minibag,&rdquo; Alert 115, July 2007, World Health Organization, Geneva. Available at file://www.who.int/medicines/publications/drugalerts/Alert_115_vincristine.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10045 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1498=[""].join("\n");
var outline_f1_29_1498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708854\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10518612\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234244\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234199\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234221\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234200\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528839\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234201\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234173\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234158\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234176\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234250\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234174\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349176\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234253\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234242\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234179\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234162\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234239\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234167\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234191\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234169\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10517724\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234207\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10517725\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324097\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234171\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234181\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234161\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234178\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10045|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/7/42100?source=related_link\">",
"      Vincristine (conventional): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=related_link\">",
"      Vincristine (conventional): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_29_1499="Opiate receptor activity";
var content_f1_29_1499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opiate receptor activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Opiate receptor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pharmacologic effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        mu (&micro;)",
"       </td>",
"       <td>",
"        Analgesia, miosis, respiratory depression, euphoria,",
"physical dependence, suppression of opiate withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        kappa (k)",
"       </td>",
"       <td>",
"        Spinal analgesia, does not suppress opiate withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        sigma (&sigma;)",
"       </td>",
"       <td>",
"        Dysphoria, hallucinations, respiratory and vasomotor",
"stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        delta (&Delta;)",
"       </td>",
"       <td>",
"        Unclear",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1499=[""].join("\n");
var outline_f1_29_1499=null;
var title_f1_29_1500="Lung abscess bacteriology";
var content_f1_29_1500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bacteriology of lung abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organisms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        Total cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aerobic bacteria only",
"       </td>",
"       <td>",
"        10 (11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaerobes only",
"       </td>",
"       <td>",
"        43 (46)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed aerobes and anaerobes",
"       </td>",
"       <td>",
"        40 (43)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\" colspan=\"2\">",
"        Predominant isolates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Aerobes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        13 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        9 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Klebsiella pneumoniae",
"       </td>",
"       <td>",
"        7 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        7 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Streptococcus pneumoniae",
"       </td>",
"       <td>",
"        6 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Anaerobes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Peptostreptococcus",
"       </td>",
"       <td>",
"        40 (12)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fusobacterium nucleatum",
"       </td>",
"       <td>",
"        34 (5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Prevotella (black-pigmented)",
"       </td>",
"       <td>",
"        32 (1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bartlett JG. Chest 1987; 91:901.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1500=[""].join("\n");
var outline_f1_29_1500=null;
var title_f1_29_1501="Dressings for EB infected wounds";
var content_f1_29_1501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dressing for epidermolysis bullosa (EB) infected wounds",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"8%\">",
"     </colgroup>",
"     <colgroup span=\"4\" width=\"23%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Recommended dressings for infected and critically colonized wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Type",
"       </td>",
"       <td class=\"subtitle2\">",
"        Brand",
"       </td>",
"       <td class=\"subtitle2\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle2\">",
"        Contraindication",
"       </td>",
"       <td class=\"subtitle2\">",
"        Wear time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Honey",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Malodorous wounds",
"        </p>",
"        Infection/critical colonization",
"       </td>",
"       <td>",
"        <p>",
"         Pain",
"        </p>",
"        <p>",
"         Environments where insects abound",
"        </p>",
"        May need to use over primary dressings",
"       </td>",
"       <td>",
"        <p>",
"         Change every three to seven days",
"        </p>",
"        May need to change secondary dressing more frequently due to increased exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Algivon",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medihoney Gel Sheet",
"       </td>",
"       <td>",
"        Sensitive wounds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Replace when no evidence of gel sheet remains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesitran ointment S",
"       </td>",
"       <td>",
"        Sensitive wounds",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Apply at each dressing change",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Silver",
"       </td>",
"       <td>",
"        Mepilex AG",
"       </td>",
"       <td>",
"        Wounds requiring foam dressing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urgotul Silver/SSD",
"       </td>",
"       <td>",
"        Primary dressing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PolyMem Silver",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aquacel Ag",
"       </td>",
"       <td>",
"        EB simplex with diabetes mellitus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Suprasorb X + PHMB (polyhexanide)",
"       </td>",
"       <td>",
"        <p>",
"         Pain",
"        </p>",
"        Itching",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Daily for optimum pain relief and cooling effect",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Cutimed Sorbact",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        As dictated by strikethrough on secondary dressing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        PolyMem",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        When strikethrough observed",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Crystacide",
"       </td>",
"       <td>",
"        Superficial infection",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1501=[""].join("\n");
var outline_f1_29_1501=null;
var title_f1_29_1502="Bleeding risk gastric varices";
var content_f1_29_1502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bleeding according to site of gastric varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 268px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of a prospective study of 568 consecutive patients with gastric varices. Isolated gastric varices in the fundus (IGV1) bled much more frequently (about 90 percent) than either gastroesophageal varices (GOV1 and GOV2) or isolated gastric varices at other loci in the stomach (IGV2).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sarin SK, Lahoti D, Saxena SP, et al. Hepatology 1992; 16:1343.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1502=[""].join("\n");
var outline_f1_29_1502=null;
var title_f1_29_1503="Immature cataract";
var content_f1_29_1503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immature cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 188px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dilated penlight photo of an immature cataract demonstrates that this amount of opacity transmits a red reflex and allows viewing of the posterior pole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_29_1503=[""].join("\n");
var outline_f1_29_1503=null;
